

Author Index Volume 55 (2017)

The issue number is given in front of the pagination

- Aalten, P., see Freeze, W.M. (1) 333–342
Aalten, P., see Jansen, W.J. (2) 679–689
Abdin, E., see Peh, C.X. (2) 823–833
Abrevaya, S., L. Sedeño, S. Fitipaldi, D. Pineda, F. Lopera, O. Buritica, A. Villegas, C. Bustamante, D. Gomez, N. Trujillo, R. Pautassi, A. Ibáñez and A.M. García, The Road Less Traveled: Alternative Pathways for Action-Verb Processing in Parkinson's Disease (4) 1429–1435
Acevedo, L.A., see Fisher, C.L. (1) 391–410
Adorni, M.P., see Zimetti, F., (1) 315–320
Ahn, S., see Kim, H.-R. (1) 137–146
Ai, L., see Chang, P. (1) 77–87
Alafuzoff, I., see Laiterä, T. (3) 995–1003
Alciato, F., see Sainaghi, P.P. (1) 59–65
Alcolea, D., see Carmona-Iragui, M. (4) 1489–1496
Alcolea, D., see Gamir-Morralla, A. (4) 1327–1333
Alexander, R.C., see Cebers, G. (3) 1039–1053
Allali, G., see Beauchet, O. (3) 965–971
Allan, S.M., see Martins, I.V.A. (3) 915–932
Alonso, J.F., see Ochoa, J.F. (3) 1195–1205
Altiner, A., see Teipel, S.J. (4) 1379–1394
Amano, N., see Okamoto, N. (2) 575–583
An, H., B. Choi, K.-w. Park, D.-H. Kim, D.-W. Yang, C.H. Hong, S.Y. Kim and S.-H. Han, The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects (2) 727–735
Anbarjafari, G., see Beheshti, I. (4) 1571–1582
Andel, R., see Pařízková, M. (3) 951–964
Anderson, A., see McClure, R. (2) 797–811
Anderson, M., F. Xu, M.-H. Ou-Yang, J. Davis, W.E. Van Nostrand and J.K. Robinson, Intensive 'Brain Training' Intervention Fails to Reduce Amyloid Pathologies or Cognitive Deficits in Transgenic Mouse Models of Alzheimer's Disease (3) 1109–1121
Andreotti, J., T. Dierks, L.-O. Wahlund and M. Grieder, Diverging Progression of Network Disruption and Atrophy in Alzheimer's Disease and Semantic Dementia (3) 981–993
Anfossi, M., see Cupidi, C. (3) 1249–1259
Antoine, P., see Wawrziczny, E. (2) 703–716
Antonelli, F., see Buongiorno, M. (3) 1261–1272
Araque Caballero, M.A., S. Klöppel, M. Dichgans, M. Ewers and for the Alzheimer's Disease Neuroimaging Initiative, Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects (1) 343–358
Ardekani, B.A., E. Bermudez, A.M. Mubeen, A.H. Bachman and for the Alzheimer's Disease Neuroimaging Initiative, Prediction of Incipient Alzheimer's Disease Dementia in Patients with Mild Cognitive Impairment (1) 269–281
Argueta, J., see Coskun, P. (2) 737–748
Ariga, H., see Kitamura, Y. (1) 67–72
Arnerić, S.P., R. Batrla-Utermann, L. Beckett, T. Bittner, K. Blennow, L. Carter, R. Dean, S. Engelborghs, J. Genius, M.F. Gordon, J. Hitchcock, J. Kaplow, J. Luthman, R. Meibach, D. Raunig, K. Romero, M.N. Samtani, M. Savage, L. Shaw, D. Stephenson, R.M. Umek, H. Vanderstichele, B. Willis and S. Yule, Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team (1) 19–35
Arnold, S.E., see Quarmley, M. (4) 1497–1507
Arreche, S.C., see de la Rubia Ortí, J.E. (3) 899–903
Arroyo-Anlló, E.M., A.T. Bouston, M.-N. Fargeau, B.O. Baz and R. Gil, Self-Consciousness Deficits in Alzheimer's Disease and Frontotemporal Dementia (4) 1437–1443
Ashihara, E., see Kitamura, Y. (1) 67–72
Assini, A.G., see Miranda, L.F.J.R. (2) 539–549
Asthana, S., see Darst, B.F. (2) 473–484
Azuma, S., see Kazui, H. (4) 1403–1416
Baarends, G., see Philippens, I.H. (1) 101–113
Bachman, A.H., see Ardekani, B.A. (1) 269–281
Backes, W.H., see Freeze, W.M. (1) 333–342

- Back, M.J., see Kim, H.-R. (1) 137–146
- Bang, J., see Fong, J.C. (1) 249–258
- Banks, W.A., A. Kovac, P. Majerova, K.M. Bullock, M. Shi and J. Zhang, Tau Proteins Cross the Blood-Brain Barrier (1) 411–419
- Baran, T.M., see Lin, F., (2) 669–678
- Barayuga, S.M., see Rueli, R.H.L.H. (2) 749–762
- Bargalló, N., see Grau-Rivera, O. (1) 431–443
- Barkhof, F., see Freeze, W.M. (1) 333–342
- Barkhof, F., see Hafkemeijer, A. (2) 521–537
- Barocco, F., see Zimetti, F., (1) 315–320
- Barrio, J.R., see Buongiorno, M. (3) 1261–1272
- Barton, S., see McClure, R. (2) 797–811
- Barulli, M.R., see Papazacharias, A. (3) 973–979
- Basora, M., see Buongiorno, M. (3) 1261–1272
- Batrla-Utermann, R., see Arnerić, S.P. (1) 19–35
- Bauer, C., see Prete, D.D. (4) 1549–1570
- Baz, B.O., see Arroyo-Anlló, E.M. (4) 1437–1443
- Bea Kuiperij, H., A.A.M. Versleijen, M. Beenes, N.A. Verwey, L. Benussi, A. Paterlini, G. Binetti, C.E. Teunissen, J. Raaphorst, H.J. Schelhaas, B. Küsters, Y.A.L. Pijnenburg, R. Ghidoni and M.M. Verbeek, Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study (2) 585–595
- Beauchet, O., C.P. Launay, J. Chabot, E.J. Levinoff and G. Allali, Subjective Memory Impairment and Gait Variability in Cognitively Healthy Individuals: Results from a Cross-Sectional Pilot Study (3) 965–971
- Becker, J.T., see Slachevsky, A. (4) 1595–1603
- Beckett, L., see Arnerić, S.P. (1) 19–35
- Beenes, M., see H. Bea Kuiperij, (2) 585–595
- Beesley, S., J. Olcese, C. Saunders and E.A. Bienkiewicz, Combinatorial Treatment Effects in a Cell Culture Model of Alzheimer's Disease (3) 1155–1166
- Beheshti, I., N. Maikusa, H. Matsuda, H. Demirel, G. Anbarjafari and for the Japanese-Alzheimer's Disease Neuroimaging Initiative, Histogram-Based Feature Extraction from Individual Gray Matter Similarity-Matrix for Alzheimer's Disease Classification (4) 1571–1582
- Belbin, O., see Gamir-Morralla, A. (4) 1327–1333
- Bellan, M., see Sainaghi, P.P. (1) 59–65
- Bellinger, F.P., see Rueli, R.H.L.H. (2) 749–762
- Bellinger, M.T., see Rueli, R.H.L.H. (2) 749–762
- Bendlin, B.B., see Darst, B.F. (2) 473–484
- Benejam, B., see Carmona-Iragui, M. (4) 1489–1496
- Benlloch, M., see de la Rubia Ortí, J.E. (3) 899–903
- Bennett, D.A., see Cummings, J. (3) 1131–1139
- Benussi, L., see H. Bea Kuiperij, (2) 585–595
- Bergeron, D., A. Vermette, J. De La Sablonnière, A.-M. Cayer, R. Jr. Laforce and R.W. Bouchard, Finger-to-Nose Test Findings in Alzheimer's Disease (4) 1335–1337
- Bergman, P., see Håkansson, K. (2) 645–657
- Bermudez, E., see Ardekani, B.A. (1) 269–281
- Berna, G., see Wawrziczny, E. (2) 703–716
- Bernardi, G., see Sancesario, G.M. (4) 1659–1666
- Bernardi, L., see Cupidi, C. (3) 1249–1259
- Bernini, F., see Zimetti, F., (1) 315–320
- Berry, M.J., see Rueli, R.H.L.H. (2) 749–762
- Bertolucci, P.H.F., see Cummings, J. (3) 1131–1139
- Berumen, L.C., see Mendiola-Precoma, J. (3) 1273–1283
- Bienkiewicz, E.A., see Beesley, S. (3) 1155–1166
- Binetti, G., see H. Bea Kuiperij, (2) 585–595
- Bischof, G.N., see Dronse, J. (2) 465–471
- Bittner, T., see Arnerić, S.P. (1) 19–35
- Blennow, K., see Arnerić, S.P. (1) 19–35
- Blennow, K., see Carmona-Iragui, M. (4) 1489–1496
- Blennow, K., see Darst, B.F. (2) 473–484
- Blennow, K., see Idland, A.-V. (1) 371–379
- Blennow, K., see Lewczuk, P. (1) 159–170
- Blennow, K., see Lewczuk, P. (2) 813–822
- Blennow, K., see Russell, C.L. (1) 303–313
- Blesa, R., see Carmona-Iragui, M. (4) 1489–1496
- Blesa, R., see Cummings, J. (3) 1131–1139
- Boeve, B.F., see Savica, R. (2) 559–567
- Bogdanovic, N., see Idland, A.-V. (1) 371–379
- Bohannon, R.C., see Coskun, P. (2) 737–748
- Bøhmer, T., see Ulstein, I. (2) 717–725
- Bonnet, A.-L., see Duclos, H. (2) 459–463
- Borghi, R., see Monacelli, F. (4) 1295–1306
- Bos, D., see Wolters, F.J. (3) 893–897
- Bouchard, R.W., see Bergeron, D. (4) 1335–1337
- Bougea, A., see Paraskevas, G.P. (4) 1453–1461
- Bourassa, P., see Dal-Pan, A. (1) 115–135
- Bourdoulous, M., see Dal-Pan, A. (1) 115–135
- Boustou, A.T., see Arroyo-Anlló, E.M. (4) 1437–1443
- Bouwman, F., see Jansen, W.J. (2) 679–689
- Bozzali, M., see Serra, L. (1) 421–430
- Brækhus, A., see Idland, A.-V. (1) 371–379
- Brandner, S., see Lewczuk, P. (1) 159–170
- Bravo, E., see Slachevsky, A. (4) 1595–1603
- Brem, A.-K., see Fried, P.J. (1) 89–100
- Bruni, A.C., see Cupidi, C. (3) 1249–1259
- Budamagunta, M., see Hilt, S. (4) 1667–1681

- Bullock, K.M., see Banks, W.A. (1) 411–419
- Buongiorno, M., F. Antonelli, Y. Compta, Y. Fernandez, J. Pavia, F. Lomeña, J. Ríos, I. Ramírez, J.R. García, M. Soler, A. Cámara, M. Fernández, M. Basora, F. Salazar, G. Sanchez-Etayo, F. Valldeoriola, J.R. Barrio and M.J. Martí, Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid- β and Tau in Parkinson's Disease (3) 1261–1272
- Burgmans, S., see Freeze, W.M. (1) 333–342
- Buritica, O., see Abrevaya, S. (4) 1429–1435
- Busciglio, J., see Coskun, P. (2) 737–748
- Bussè, C., see Cagnin, A. (4) 1529–1536
- Bussiere, R., see Prete, D.D. (4) 1549–1570
- Bustamante, C., see Abrevaya, S. (4) 1429–1435
- Butts, A.M., see Krishnan, K. (3) 1019–1029
- Byrro, R.M.D., see Miranda, L.F.J.R. (2) 539–549
- Byun, H.J., see Han, J.W. (2) 787–796
- Caffarra, P., see Zimetti, F., (1) 315–320
- Cagnin, A., F. Fragiaco, G. Camporese, M. Turco, C. Bussè, M. Ermani and S. Montagnese, Sleep-Wake Profile in Dementia with Lewy Bodies, Alzheimer's Disease, and Normal Aging (4) 1529–1536
- Calon, F., see Dal-Pan, A. (1) 115–135
- Calvo, A., see Grau-Rivera, O. (1) 431–443
- Cámara, A., see Buongiorno, M. (3) 1261–1272
- Camporese, G., see Cagnin, A. (4) 1529–1536
- Cantello, R., see Sainaghi, P.P. (1) 59–65
- Capellari, S., see Rumeileh, S.A. (4) 1471–1480
- Capozzo, R., see Papazacharias, A. (3) 973–979
- Cappa, S.F., see Cerami, C. (1) 183–197
- Caramelli, P., see Miranda, L.F.J.R. (2) 539–549
- Carecchio, M., see Sainaghi, P.P. (1) 59–65
- Carita, P., see Leger, D. (1) 321–331
- Carlsson, C.M., see Darst, B.F. (2) 473–484
- Carlsson, R., see Håkansson, K. (2) 645–657
- Carmona-Iragui, M., T. Santos, S. Videla, S. Fernández, B. Benejam, L. Videla, D. Alcolea, K. Blennow, R. Blesa, A. Lleó and J. Fortea, Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome (4) 1489–1496
- Carroll, B.J., see Myung, W. (1) 283–292
- Carter, L., see Arnerić, S.P. (1) 19–35
- Castillo, S.S., see de la Rubia Ortí, J.E. (3) 899–903
- Castillo-Carranza, D.L., see Nilson, A.N. (3) 1083–1099
- Cavallaro, S., see Cuccaro, D. (1) 37–52
- Cayer, A.-M., see Bergeron, D. (4) 1335–1337
- Cea, M., see Monacelli, F. (4) 1295–1306
- Cebers, G., R.C. Alexander, S.B. Haeberlein, D. Han, R. Goldwater, L. Ereshefsky, T. Olsson, N. Ye, L. Rosen, M. Russell, J. Maltby, S. Eketjäll and A.R. Kugler, AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease (3) 1039–1053
- Cerami, C., A. Dodich, L. Greco, S. Iannaccone, G. Magnani, A. Marcone, E. Pelagallo, R. Santangelo, S.F. Cappa and D. Perani, The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia (1) 183–197
- Cercignani, M., see Serra, L. (1) 421–430
- Cerulli, G., see Crispoltoni, L. (3) 1005–1017
- Chabot, J., see Beauchet, O. (3) 965–971
- Chami, M., see Prete, D.D. (4) 1549–1570
- Chang, J., see Chang, P. (1) 77–87
- Chang, P., X. Li, C. Ma, S. Zhang, Z. Liu, K. Chen, L. Ai, J. Chang and Z. Zhang, The Effects of an APOE Promoter Polymorphism on Human White Matter Connectivity during Non-Demented Aging (1) 77–87
- Chang, X., see Fraser, M.D. (4) 1321–1325
- Chapman, B.P., see Lin, F., (2) 669–678
- Chattat, R., see Mariani, E. (4) 1621–1638
- Chau, S.A., N. Herrmann, C. Sherman, J. Chung, M. Eizenman, A. Kiss and K.L. Lanctôt, Visual Selective Attention Toward Novel Stimuli Predicts Cognitive Decline in Alzheimer's Disease Patients (4) 1339–1349
- Chaudhry, F.A., see Idland, A.-V. (1) 371–379
- Checler, F., see Prete, D.D. (4) 1549–1570
- Chen, K., see Chang, P. (1) 77–87
- Chen, K., see Sun, L. (2) 777–785
- Chen, T., see Zhuang, X. (3) 1101–1108
- Chen, Y., see Zhuang, X. (3) 1101–1108
- Cheon, H.-S., see Shim, S.-M. (1) 293–301
- Cheran, G., see Huey, E.D. (2) 551–558
- Chiasserini, D., see Lewczuk, P. (1) 159–170
- Chiasserini, D., see Sancesario, G.M. (4) 1659–1666
- Cho, K.H., see Kim, Y. (2) 485–495
- Choi, B., see An, H. (2) 727–735
- Choi, J., see Myung, W. (1) 283–292
- Choi, S.H., see Myung, W. (1) 283–292
- Choi, Y., see Ryu, H.J. (4) 1395–1401
- Chong, S.A., see Peh, C.X. (2) 823–833
- Christian, B.T., see Darst, B.F. (2) 473–484
- Chua, B.Y., see Peh, C.X. (2) 823–833

- Chung, J., see Chau, S.A. (4) 1339–1349
 Chung, J.W., see Myung, W. (1) 283–292
 Cittadella R., see Cuccaro, D. (1) 37–52
 Claassen, J., see Jansen, W.J. (2) 679–689
 Clare, L., see Yates, J.A., (3) 1183–1193
 Clark, C.N., see Golden, H.L. (3) 933–949
 Clerx, L., see Freeze, W.M. (1) 333–342
 Clodomiro, A., see Cupidi, C. (3) 1249–1259
 Cohen, M.H., see Golden, H.L. (3) 933–949
 Cohen-Manheim, I., G.M. Doniger, R. Sinnreich, E.S. Simon, H. Murad, R. Pinchas-Mizrachi and J.D. Kark Body Mass Index, Height and Socioeconomic Position in Adolescence, Their Trajectories into Adulthood, and Cognitive Function in Midlife (3) 1207–1221
 Colao, R., see Cupidi, C. (3) 1249–1259
 Comi, C., see Sainaghi, P.P. (1) 59–65
 Compta, Y., see Buongiorno, M. (3) 1261–1272
 Conidi, M.E., see Cupidi, C. (3) 1249–1259
 Constantinides, V., see Paraskevas, G.P. (4) 1453–1461
 Coppola, G., see Fong, J.C. (1) 249–258
 Corsini, A., see Zimetti, F., (1) 315–320
 Coskun, P., P. Helguera, Z. Nemati, R.C. Bohannan, J. Thomas, S.E. Schriener, J. Argueta, E. Doran, D.C. Wallace, I.T. Lott and J. Busciglio, Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's Disease (2) 737–748
 Coulson, E.J., see Turnbull, M.T. (3) 1141–1154
 Crain, C.N., see Nilson, A.N. (3) 1083–1099
 Crispoltoni, L., A.M. Stabile, A. Pistilli, M. Venturelli, G. Cerulli, C. Fonte, N. Smania, F. Schena and M. Rende, Changes in Plasma β -NGF and Its Receptors Expression on Peripheral Blood Monocytes During Alzheimer's Disease Progression (3) 1005–1017
 Crutch, S.J., see Golden, H.L. (3) 933–949
 Cuccaro, D., E. Valeria De Marco, R. Cittadella and S. Cavallaro, Copy Number Variants in Alzheimer's Disease (1) 37–52
 Cui, D., see Xie, B. (2) 509–520
 Cummings, J., P. Scheltens, I. McKeith, R. Blesa, J.E. Harrison, P.H.F. Bertolucci, K. Rockwood, D. Wilkinson, W. Wijker, D.A. Bennett and R.C. Shah, Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease (3) 1131–1139
 Cupidi, C., F. Frangipane, M. Gallo, A. Clodomiro, R. Colao, L. Bernardi, M. Anfossi, M.E. Conidi, F. Vasso, S.A.M. Curcio, M. Mirabelli, N. Smirne, G. Torchia, M.G. Muraca, G. Puccio, R. Di Lorenzo, S. Zampieri, M. Romanello, A. Dardis, R.G. Maletta and A.C. Bruni, Role of Niemann-Pick Type C Disease Mutations in Dementia (3) 1249–1259
 Curcio, S.A.M., see Cupidi, C. (3) 1249–1259
 Cypess, A.M., see Fried, P.J. (1) 89–100
 Daffner, K., see Håkansson, K. (2) 645–657
 Dal-Pan, A., S. Dudonné, P. Bourassa, M. Bourdoulous, C. Tremblay, Y. Desjardins and F. Calon on behalf of the Neurophenols consortium, Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer's Disease (1) 115–135
 Damanhuri, H.A., see Ibrahim, N.F. (2) 597–612
 Dardis, A., see Cupidi, C. (3) 1249–1259
 Darst, B.F., R.L. Kosciak, A.M. Racine, J.M. Oh, R.A. Krause, C.M. Carlsson, H. Zetterberg, K. Blennow, B.T. Christian, B.B. Bendlin, O.C. Okonkwo, K.J. Hogan, B.P. Hermann, M.A. Sager, S. Asthana, S.C. Johnson and C.D. Engelman, Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease (2) 473–484
 Davey, C.S., see Vemuri, P. (3) 1069–1082
 Davies, J.R.T., see Fraser, M.D. (4) 1321–1325
 Davis, J., see Anderson, M. (3) 1109–1121
 Dawes, M., see McClure, R. (2) 797–811
 De Blasi, R., see Papazacharias, A. (3) 973–979
 De Deyn, P.P., see Dekens, D.W. (2) 763–776
 De Deyn, P.P., see Goossens, J. (1) 53–58
 de França Bram, J.M., see Sarno, T.A. (4) 1445–1451
 de la Monte, S.M., M. Tong, I. Schiano and J. Didsbury, Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease (2) 849–864
 de la Rubia Orti, J.E., S.S. Castillo, M. Benlloch, M.J. Rochina, S.C. Arreche and M.P. García-Pardo
 De La Sablonnière, J., see Bergeron, D. (4) 1335–1337
 de La Sayette, V., see Duclos, H. (2) 459–463
 De, S., see Fisher, C.L. (1) 391–410
 Dean, R., see Arnerić, S.P. (1) 19–35
 Debayle, D., see Prete, D.D. (4) 1549–1570
 Dekens, D.W., P.J.W. Naudé, S. Engelborghs, Y. Vermeiren, D. Van Dam, R.C.O. Voshaar, U.L.M. Eisel and P.P. De Deyn, Neutrophil Gelatinase-Associated Lipocalin and its

- Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression (2) 763–776
- Delgado, C., see Slachevsky, A. (4) 1595–1603
- Demirel, H., see Beheshti, I. (4) 1571–1582
- Dengler-Crish, C.M., M.A. Smith and G.N. Wilson, Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease (4) 1605–1619
- Desgranges, B., see Duclos, H. (2) 459–463
- Desjardins Y., see Dal-Pan, A. (1) 115–135
- Devanand, D.P., see Huey, E.D. (2) 551–558
- Dewing, A.S.T., see Rueli, R.H.L.H. (2) 749–762
- Di Domenico, C., see Serra, L. (1) 421–430
- Di Lorenzo, R., see Cupidi, C. (3) 1249–1259
- Di Santo, S.G., see Sancesario, G.M. (4) 1659–1666
- Dichgans, M., see Araque Caballero, M.Á. (1) 343–358
- Didsbury, J., see de la Monte, S.M. (2) 849–864
- Dierks, T., see Andreotti, J. (3) 981–993
- Dobson, R.J.B., see Voyle, N. (4) 1417–1427
- Dodich, A., see Cerami, C. (1) 183–197
- Domínguez-Prieto, M., A. Velasco, L. Vega, A. Taberero and J.M. Medina, Aberrant Colocalization of Synaptic Proteins Promoted by Alzheimer's Disease Amyloid- β Peptides: Protective Effect of Human Serum Albumin (1) 171–182
- Doniger, G.M., see Cohen-Manheim, I. (3) 1207–1221
- Dopper, E.G.P., see Hafkemeijer, A. (2) 521–537
- Doraiswamy, P.M., see Lin, K.A. (3) 1123–1130
- Doran, E., see Coskun, P. (2) 737–748
- Doverskog, M., see Philippens, I.H. (1) 101–113
- Dragano, N., see Kara, K. (1) 359–369
- Dronse, J., K. Fliessbach, G.N. Bischof, B. von Reutern, J. Faber, J. Hammes, G. Kuhnert, B. Neumaier, O.A. Onur, J. Kukolja, T. van Eimeren, F. Jessen, G.R. Fink, T. Klockgether and A. Drzezga, In vivo Patterns of Tau Pathology, Amyloid- β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease (2) 465–471
- Drzezga, A., see Dronse, J. (2) 465–471
- Du, H., see Gauba, E. (4) 1351–1362
- Dubois, A., see Leger, D. (1) 321–331
- Ducharme, F., see Wawrzyszyn, E. (2) 703–716
- Duclos, H., V. de La Sayette, A.-L. Bonnet, A. Viard, F. Eustache, B. Desgranges and M. Laisney, Social Cognition in the Frontal Variant of Alzheimer's Disease: A Case Study (2) 459–463
- Dudonné, S., see Dal-Pan, A. (1) 115–135
- Duffy, J.R., see Krishnan, K. (3) 1019–1029
- Duque, J.E., see Ochoa, J.F. (3) 1195–1205
- Durani, L.W., see Ibrahim, N.F. (2) 597–612
- Durgerian, S., see Reiter, K. (4) 1363–1377
- Edwards, K., see Savica, R. (2) 559–567
- Eichler, T., see Wucherer, D. (2) 691–701
- Eisel, U.L.M., see Dekens, D.W. (2) 763–776
- Eizenman, M., see Chau, S.A. (4) 1339–1349
- Eketjäll, S., see Cebers, G. (3) 1039–1053
- Elbaz, M., see Leger, D. (1) 321–331
- Elbing, U., see Muller, S. (4) 1463–1469
- Engelborghs, S., see Arnerić, S.P. (1) 19–35
- Engelborghs, S., see Dekens, D.W. (2) 763–776
- Engelborghs, S., see Goossens, J. (1) 53–58
- Engelborghs, S., see Lewczuk, P. (1) 159–170
- Engelman, C.D., see Darst, B.F. (2) 473–484
- Engels, Y., see Mariani, E. (4) 1621–1638
- English, K.C., see Nilson, A.N. (3) 1083–1099
- Erbel, R., see Kara, K. (1) 359–369
- Ereshefsky, L., see Cebers, G. (3) 1039–1053
- Eri, L.M., see Idland, A.-V. (1) 371–379
- Ermani, M., see Cagnin, A. (4) 1529–1536
- Eusebi, P., see Lewczuk, P. (2) 813–822
- Eustache, F., see Duclos, H. (2) 459–463
- Evdokimidis, I., see Paraskevas, G.P. (4) 1453–1461
- Ewers, M., see Araque Caballero, M.Á. (1) 343–358
- Faber, J., see Dronse, J. (2) 465–471
- Fagan, A.M., see Lewczuk, P. (2) 813–822
- Fargeau, M.-N., see Arroyo-Anlló, E.M. (4) 1437–1443
- Fariás, G.A., see Slachevsky, A. (4) 1595–1603
- Fariás, M., see Slachevsky, A. (4) 1595–1603
- Favari, E., see Zimetti, F. (1) 315–320
- Feng, T.L., see Robillard, J.M. (1) 219–229
- Fenoglio, C., see Sainaghi, P.P. (1) 59–65
- Fernández, M., see Buongiorno, M. (3) 1261–1272
- Fernández, S., see Carmona-Iragui, M. (4) 1489–1496
- Fernandez, Y., see Buongiorno, M. (3) 1261–1272
- Ferreira, D., see Rivero-Santana, A. (2) 625–644
- Ferrer, I., see Gamir-Morralla, A. (4) 1327–1333
- Ferri, N., see Zimetti, F. (1) 315–320
- Fink, G.R., see Dronse, J. (2) 465–471
- Fischer, C.E., see Kim, J. (1) 381–389
- Fischer, C.E., see Sennik, S. (4) 1519–1528
- Fisher, C.L., R.J. Resnick, S. De, L.A. Acevedo, K.P. Lu, F.C. Schroeder and L.K. Nicholson, Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of A β PP into Amyloidogenic Processing Pathway (1) 391–410

- Fitipaldi, S., see Abrevaya, S. (4) 1429–1435
- Flach, K., see Lewczuk, P. (1) 159–170
- Fleiner, T., S. Leucht, H. Förstl, W. Zijlstra and P. Haussermann, Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review (4) 1583–1594
- Fliessbach, K., see Dronse, J. (2) 465–471
- Flores, P., see Slachevsky, A. (4) 1595–1603
- Folarin, A., see Voyle, N. (4) 1417–1427
- Fong, J.C., J.C. Rojas, J. Bang, A. Legati, K.P. Rankin, S. Forner, Z.A. Miller, A.M. Karydas, G. Coppola, C.K. Grouse, J. Ralph, B.L. Miller and M.D. Geschwind, Genetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral Neuropathy (1) 249–258
- Fonte, C., see Crispoltoni, L. (3) 1005–1017
- Forlenza, O.V., see Sarno, T.A. (4) 1445–1451
- Forner, S., see Fong, J.C. (1) 249–258
- Förstl, H., see Fleiner, T. (4) 1583–1594
- Fortea, J., see Carmona-Iragui, M. (4) 1489–1496
- Fortea, J., see Gamir-Morralla, A. (4) 1327–1333
- Foscarin, S., see Raha, A.A. (1) 199–217
- Foulkes, A.J.M., see Golden, H.L. (3) 933–949
- Foxe, J.J., see Lin, F. (2) 669–678
- Fragiacomo, F., see Cagnin, A. (4) 1529–1536
- Franco, O.H., see Wolters, F.J. (3) 893–897
- Frangipane, F., see Cupidi, C. (3) 1249–1259
- Fraser, M.D., J.R.T. Davies and X. Chang, New Gold in Them Thar Hills: Testing a Novel Supply Route for Plant-Derived Galanthamine (4) 1321–1325
- Freeze, W.M., H.I.L. Jacobs, E.H. Gronenschild, J.F.A. Jansen, S. Burgmans, P. Aalten, L. Clerx, S.J. Vos, M.A. van Buchem, F. Barkhof, W.M. van der Flier, M.M. Verbeek, M.O. Rikkert, W.H. Backes and F.R. Verhey, on behalf of the LeARN project, White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid- β (1) 333–342
- Fried, P.J., L. Schilberg, A.-K. Brem, S. Saxena, B. Wong, A.M. Cypess, E.S. Horton and A. Pascual-Leone, Humans with Type-2 Diabetes Show Abnormal Long-Term Potentiation-Like Cortical Plasticity Associated with Verbal Learning Deficits (1) 89–100
- Friedland, R.P., see Raha, A.A. (1) 199–217
- Frihagen, F., see Idland, A.-V. (1) 371–379
- Fujikura, M., see Iwahara, N. (3) 1235–1247
- Galimberti, D., see Sainaghi, P.P. (1) 59–65
- Galimberti, D., see Zimetti, F. (1) 315–320
- Gallo, M., see Cupidi, C. (3) 1249–1259
- Galvin, J.E., see Ryu, H.J. (4) 1395–1401
- Gamir-Morralla, A., O. Belbin, J. Fortea, D. Alcolea, I. Ferrer, A. Lleó and T. Iglesias, Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid (4) 1327–1333
- García, J.R., see Buongiorno, M. (3) 1261–1272
- García, A.M., see Abrevaya, S. (4) 1429–1435
- García-Alcocer, G., see Mendiola-Precoma, J. (3) 1273–1283
- García-Pardo, M.P., see de la Rubia Ortí, J.E. (3) 899–903
- Garrido, C., see Slachevsky, A. (4) 1595–1603
- Gattaz, W.F., see Sarno, T.A. (4) 1445–1451
- Gaub, E., L. Guo and H. Du, Cyclophilin D Promotes Brain Mitochondrial FIFO ATP Synthase Dysfunction in Aging Mice (4) 1351–1362
- Gay, A.S., see Prete, D.D. (4) 1549–1570
- Gažová, I., see Pařízková, M. (3) 951–964
- Gelpi, E., see Grau-Rivera, O. (1) 431–443
- Genius, J., see Arnerić, S.P. (1) 19–35
- Gerson, J.E., see Nilson, A.N. (3) 1083–1099
- Geschwind, M.D., see Fong, J.C. (1) 249–258
- Ghidoni, R., see H. Bea Kuiperij, (2) 585–595
- Gielen, J., see Goossens, J. (1) 53–58
- Gil, R., see Arroyo-Anlló, E.M. (4) 1437–1443
- Giulietti, G., see Serra, L. (1) 421–430
- Gobom, J., see Russell, C.L. (1) 303–313
- Goeman, J., see Goossens, J. (1) 53–58
- Golden, H.L., C.N. Clark, J.M. Nicholas, M.H. Cohen, C.F. Slattery, R.W. Paterson, A.J.M. Foulkes, J.M. Schott, C.J. Mummery, S.J. Crutch and J.D. Warren, Music Perception in Dementia (3) 933–949
- Goldwater, R., see Cebers, G. (3) 1039–1053
- Gomes, K.B., see Miranda, L.F.J.R. (2) 539–549
- Gomez, D., see Abrevaya, S. (4) 1429–1435
- Gong, Q., see Hilt, S. (4) 1667–1681
- Goossens, J., J. Laton, J.V. Schependom, J. Gielen, H. Struyfs, S. Van Mossevelde, T. Van den Bossche, J. Goeman, P.P. De Deyn, A. Sieben, J.-J. Martin, C. Van Broeckhoven, J. van der Zee, S. Engelborghs and G. Nagels, EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration (1) 53–58
- Gordon, M.F., see Arnerić, S.P. (1) 19–35
- Gore, J.C., see McClure, R. (2) 797–811
- Grafman, J., see Huey, E.D. (2) 551–558
- Granholm, A.-C., see Håkansson, K. (2) 645–657

- Grau-Rivera, O., A. Calvo, N. Bargalló, G.C. Monté, C. Nos, A. Lladó, J.L. Molinuevo, E. Gelpi and R. Sánchez-Valle, Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia (1) 431–443
- Greco, L., see Cerami, C. (1) 183–197
- Grieder, M., see Andreotti, J. (3) 981–993
- Gronenschild, E.H., see Freeze, W.M. (1) 333–342
- Grouse, C.K., see Fong, J.C. (1) 249–258
- Guo, J.-P., see Lee, M. (3) 1175–1182
- Guo, L., see Gauba, E. (4) 1351–1362
- Gupta, P., see Nilson, A.N. (3) 1083–1099
- Gureviciene, I., K. Gurevicius, E. Mugantseva, M. Kislin, L. Khiroug and H. Tanila, Amyloid Plaques Show Binding Capacity of Exogenous Injected Amyloid- β (1) 147–157
- Gurevicius, K., see Gureviciene, I. (1) 147–157
- Guzmán-Martínez, L., see Slachevsky, A. (4) 1595–1603
- Haapasalo, A., see Laiterä, T. (3) 995–1003
- Haerberlein, S.B., see Cebers, G. (3) 1039–1053
- Hafkemeijer, A., C. Möller, E.G.P. Dopfer, L.C. Jiskoot, A.A. van den Berg-Huysmans, J.C. van Swieten, W.M. van der Flier, H. Vrenken, Y.A.L. Pijnenburg, F. Barkhof, P. Scheltens, J. van der Grond and S.A.R.B. Rombouts, A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease (2) 521–537
- Hagen, C., see Savica, R. (2) 559–567
- Håkansson, K., A. Ledreux, K. Daffner, Y. Terjestam, P. Bergman, R. Carlsson, M. Kivipelto, B. Winblad, A.-C. Granholm and A.K.H. Mohammed, BDNF Responses in Healthy Older Persons to 35 Minutes of Physical Exercise, Cognitive Training, and Mindfulness: Associations with Working Memory Function (2) 645–657
- Hall, A., see Pekkala, T. (3) 1055–1067
- Ham, J.H., see Kim, Y. (2) 485–495
- Hamaguchi, T., see Noguchi-Shinohara, M. (3) 905–913
- Hamasaki, H., H. Honda, T. Okamoto, S. Koyama, S.O. Suzuki, T. Ohara, T. Ninomiya, Y. Kiyohara and T. Iwaki, Recent Increases in Hippocampal Tau Pathology in the Aging Japanese Population: The Hisayama Study (2) 613–624
- Hamezah, H.S., see Ibrahim, N.F. (2) 597–612
- Hammes, J., see Dronse, J. (2) 465–471
- Han, D., see Cebers, G. (3) 1039–1053
- Han, J.W., H. Lee, J.W. Hong, K. Kim, T. Kim, H.J. Byun, J.W. Ko, J.C. Youn, S.-H. Ryu, N.-J. Lee, C.-U. Pae and K.W. Kim, Multimodal Cognitive Enhancement Therapy for Patients with Mild Cognitive Impairment and Mild Dementia: A Multi-Center, Randomized, Controlled, Double-Blind, Crossover Trial (2) 787–796
- Han, J.W., see Jacob, L. (1) 259–267
- Han, J.-Y., see Ryu, H.J. (4) 1395–1401
- Han, S.-H., see An, H. (2) 727–735
- Han, S.-H., see Myung, W. (1) 283–292
- Han, S.-H., see Ryu, H.J. (4) 1395–1401
- Handels, R.L.H., see Jansen, W.J. (2) 679–689
- Hansson, K., see Russell, C.L. (1) 303–313
- Hansson, O., see Idland, A.-V. (1) 371–379
- Hardman, R.J., see Kennedy, G. (1) 1–18
- Harrington, C.A., see Lusardi, T.A. (3) 1223–1233
- Harrison, J.E., see Cummings, J. (3) 1131–1139
- Haussermann, P., see Fleiner, T. (4) 1583–1594
- He, R., see Tong, Z. (3) 1031–1038
- Helguera, P., see Coskun, P. (2) 737–748
- Helisalmi, S., see Laiterä, T. (3) 995–1003
- Henderson, J.W., see Raha, A.A. (1) 199–217
- Hermann, B.P., see Darst, B.F. (2) 473–484
- Hernández, A.M., see Ochoa, J.F. (3) 1195–1205
- Herrmann, N., see Chau, S.A. (4) 1339–1349
- Hertel, J., see Wucherer, D. (2) 691–701
- Heymann, P., see Muller, S. (4) 1463–1469
- Hideg, K., see Hilt, S. (4) 1667–1681
- Hijioka, M., see Kitamura, Y. (1) 67–72
- Hilt, S., T. Tang, J.H. Walton, M. Budamagunta, I. Maezawa, T. Kálai, K. Hideg, V. Singh, H. Wulff, Q. Gong, L.-W. Jin, A. Louie and J.C. Voss, A Metal-Free Method for Producing MRI Contrast at Amyloid- β (4) 1667–1681
- Hiltunen, M., see Laiterä, T. (3) 995–1003
- Hiltunen, M., see Russell, C.L. (1) 303–313
- Hisahara, S., see Iwahara, N. (3) 1235–1247
- Hitchcock, J., see Arnerić, S.P. (1) 19–35
- Hoff, E., see Jansen, W.J. (2) 679–689
- Hoffmann, W., see Teipel, S.J. (4) 1379–1394
- Hoffmann, W., see Wucherer, D. (2) 691–701
- Hofman, A., see Wolters, F.J. (3) 893–897
- Hogan, K.J., see Darst, B.F. (2) 473–484
- Hollman, J.H., see Savica, R. (2) 559–567
- Holzer, M., see Lewczuk, P. (1) 159–170
- Honda, H., see Hamasaki, H. (2) 613–624
- Hong, C.H., see An, H. (2) 727–735
- Hong, J.W., see Han, J.W. (2) 787–796
- Hoogmoed, J., see Jansen, W.J. (2) 679–689
- Hort, J., see Pařízková, M. (3) 951–964
- Horton, E.S., see Fried, P.J. (1) 89–100

- Horvath, S., see Nemeth, V.L. (3) 865–880
- Houston, S., see Petersen, S. (2) 569–574
- Huang, F. see Shen, Y. (2) 835–847
- Huey, E.D., S. Lee, G. Cheran, J. Grafman, D.P. Devanand and for the Alzheimer's Disease Neuroimaging Initiative, Brain Regions Involved in Arousal and Reward Processing are Associated with Apathy in Alzheimer's Disease and Frontotemporal Dementia (2) 551–558
- Huovinen, J., see Laiterä, T. (3) 995–1003
- Iannaccone, S., see Cerami, C. (1) 183–197
- Ibáñez, A., see Abrevaya, S. (4) 1429–1435
- Ibrahim, N.F., D. Yanagisawa, L.W. Durani, H.S. Hamezah, H.A. Damanhuri, W.Z.W. Ngah, M. Tsuji, Y. Kiuchi, K. Ono and I. Tooyama, Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in A β PP/PS1 Mice (2) 597–612
- Idland, A.-V., T.B. Wyller, R. Støen, L.M. Eri, F. Frihagen, J. Ræder, F.A. Chaudhry, O. Hansson, H. Zetterberg, K. Blennow, N. Bogdanovic, A. Brækhus and L.O. Watne, Preclinical Amyloid- β and Axonal Degeneration Pathology in Delirium (1) 371–379
- Igase, K., see Igase, M. (4) 1481–1487
- Igase, M., M. Ohara, K. Igase, T. Kato, Y. Okada, M. Ochi, Y. Tabara, K. Kohara and Y. Ohyagi, Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People (4) 1481–1487
- Iglesias, T., see Gamir-Morralla, A. (4) 1327–1333
- Ikedo, T., see Noguchi-Shinohara, M. (3) 905–913
- Ikram, M.A., see Wolters, F.J. (3) 893–897
- Imbimbo, B.P., see Papazacharias, A. (3) 973–979
- Impact of the Relationship of Stress and the Immune System in the Appearance of Alzheimer's Disease (3) 899–903
- Inden, M., see Kitamura, Y. (1) 67–72
- Ishii, K., see Kazui, H. (4) 1403–1416
- Iwahara, N., S. Hisahara, J. Kawamata, A. Matsumura, K. Yokokawa, T. Saito, M. Fujikura, T. Manabe, H. Suzuki, T. Matsushita, S. Suzuki and S. Shimohama, Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APP^{swe}/PS1^{dE9} Mice (3) 1235–1247
- Iwaki, T., see Hamasaki, H. (2) 613–624
- Jääskeläinen, J.E., see Laiterä, T. (3) 995–1003
- Jack Jr, C.R., see Vemuri, P. (3) 1069–1082
- Jack Jr., C.R., see Krishnan, K. (3) 1019–1029
- Jacob, L., J.W. Han, T.H. Kim, J.H. Park, S.B. Lee, J.J. Lee, S.-H. Ryu, S.-K. Kim, J.C. Yoon, J.H. Jhoo, J.L. Kim, K.P. Kwak, S.W. Moon, B.J. Kim, D.Y. Lee and K.W. Kim, How Different are Quality of Life Ratings for People with Dementia Reported by Their Family Caregivers from Those Reported by the Patients Themselves? (1) 259–267
- Jacobs, A., see Lin, F., (2) 669–678
- Jacobs, H.I.L., see Freeze, W.M. (1) 333–342
- Jang, J.-W., see Kim, H.-R. (1) 137–146
- Jansen, J.F.A., see Freeze, W.M. (1) 333–342
- Jansen, W.J., R.L.H. Handels, P.J. Visser, P. Aalten, F. Bouwman, J. Claassen, P. van Domburg, E. Hoff, J. Hoogmoed, A.F.G. Leentjens, M.O. Rikkert, A.M. Oleksik, M. Smid, P. Scheltens, C. Wolfs, F. Verhey and I.H.G.B. Ramakers, The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients (2) 679–689
- Janve, V., see McClure, R. (2) 797–811
- Jeon, J.-P., see Shim, S.-M. (1) 293–301
- Jerome, W.G., see McClure, R. (2) 797–811
- Jessen, F., see Dronse, J. (2) 465–471
- Jhoo, J.H., see Jacob, L. (1) 259–267
- Jia, J., see Tong, Z. (3) 1031–1038
- Jiang, G., see Zhuang, X. (3) 1101–1108
- Jiang, L., see Xie, B. (2) 509–520
- Jin, L.-W., see Hilt, S. (4) 1667–1681
- Jiskoot, L.C., see Hafkemeijer, A. (2) 521–537
- Jo, C., see Shim, S.-M. (1) 293–301
- Joaquim, H.P.G., see Sarno, T.A. (4) 1445–1451
- Jöckel, K.-H., see Kara, K. (1) 359–369
- Johansson, M., see Philippens, I.H. (1) 101–113
- Johnson, S.C., see Darst, B.F. (2) 473–484
- Johnston, C., see Voyle, N. (4) 1417–1427
- Jokisch, M., see Kara, K. (1) 359–369
- Josephs, K.A., see Krishnan, K. (3) 1019–1029
- Jr. Laforce, R., see Bergeron, D. (4) 1335–1337
- Kabadi, S., see Quarmley, M. (4) 1497–1507
- Kálai, T., see Hilt, S. (4) 1667–1681
- Kälsch, H., see Kara, K. (1) 359–369
- Kanemoto, H., see Kazui, H. (4) 1403–1416
- Kang, H.S., see Myung, W. (1) 283–292
- Kantarci, K., see Vemuri, P. (3) 1069–1082
- Kapaki, E., see Paraskevas, G.P. (4) 1453–1461
- Kaplow, J., see Arnerić, S.P. (1) 19–35
- Kara, K., A.A. Mahabadi, C. Weimar, A. Winkler, T. Neumann, H. Kälsch, N. Dragano, S. Moebus, R. Erbel, K.-H. Jöckel and M. Jokisch,

- N-Terminal Pro-B Type Natriuretic Peptide is Associated with Mild Cognitive Impairment in the General Population (1) 359–369
- Kark, J.D., see Cohen-Manheim, I. (3) 1207–1221
- Karydas, A.M., see Fong, J.C. (1) 249–258
- Kasselimis, D., see Paraskevas, G.P. (4) 1453–1461
- Kato, T., see Igase, M. (4) 1481–1487
- Kawamata, J., see Iwahara, N. (3) 1235–1247
- Kayed, R., see Nilson, A.N. (3) 1083–1099
- Kazui, H., R. Takahashi, Y. Yamamoto, K. Yoshiyama, H. Kanemoto, Y. Suzuki, S. Sato, S. Azuma, T. Suehiro, E. Shimosegawa, K. Ishii and T. Tanaka, Neural Basis of Apathy in Patients with Amnesic Mild Cognitive Impairment (4) 1403–1416
- Keller, F., see Teipel, S.J. (4) 1379–1394
- Kelly, D.A., see Reiter, K. (4) 1363–1377
- Kennedy, G., R.J. Hardman, H. Macpherson, A.B. Scholey and A. Pipingas, How Does Exercise Reduce the Rate of Age-Associated Cognitive Decline? A Review of Potential Mechanisms (1) 1–18
- Kennedy, K., see Lee, M. (3) 1175–1182
- Kepp, K.P., Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease (2) 447–457
- Kergoat, M.-J., see Wawrziczny, E. (2) 703–716
- Khiroug, L., see Gureviciene, I. (1) 147–157
- Kiddle, S.J., see Voyle, N. (4) 1417–1427
- Kilimann, I., see Teipel, S.J. (4) 1379–1394
- Kilimann, I., see Wucherer, D. (2) 691–701
- Kim, B.J., see Jacob, L. (1) 259–267
- Kim, B.J., see Kim, H.-R. (1) 137–146
- Kim, D.-H., see An, H. (2) 727–735
- Kim, D.K., see Myung, W. (1) 283–292
- Kim, H.-R., Y.H. Park, J.-W. Jang, S.Y. Park, M.J. Wang, M.J. Baek, B.J. Kim, S. Ahn and S.Y. Kim, Visual Rating of Posterior Atrophy as a Marker of Progression to Dementia in Mild Cognitive Impairment Patients (1) 137–146
- Kim, J., T.A. Schweizer, C.E. Fischer and D.G. Munoz, The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease (1) 381–389
- Kim, J.L., see Jacob, L. (1) 259–267
- Kim, K., see Han, J.W. (2) 787–796
- Kim, K.W., see Han, J.W. (2) 787–796
- Kim, K.W., see Jacob, L. (1) 259–267
- Kim, M., see Ryu, H.J. (4) 1395–1401
- Kim, S., see Myung, W. (1) 283–292
- Kim, S., see Myung, W. (1) 283–292
- Kim, S.-K., see Jacob, L. (1) 259–267
- Kim, S.Y., see An, H. (2) 727–735
- Kim, S.Y., see Kim, H.-R. (1) 137–146
- Kim, S.Y., see Myung, W. (1) 283–292
- Kim, S.Y., see Myung, W. (1) 283–292
- Kim, T., see Han, J.W. (2) 787–796
- Kim, T.H., see Jacob, L. (1) 259–267
- Kim, Y., D. Lee, K.H. Cho, J.J. Lee, J.H. Ham, B.S. Ye, S.-K. Lee, J.-M. Lee, Y.H. Sohn and P.H. Lee, Cognitive and Neuroanatomical Correlates in Early Versus Late Onset Parkinson's Disease Dementia (2) 485–495
- Kimoto, Y., see Kitamura, Y. (1) 67–72
- Kincses, Z.T., see Nemeth, V.L. (3) 865–880
- Király, A., see Nemeth, V.L. (3) 865–880
- Kislin, M., see Gureviciene, I. (1) 147–157
- Kiss, A., see Chau, S.A. (4) 1339–1349
- Kitamura, Y., M. Inden, Y. Kimoto, K. Takata, D. Yanagisawa, M. Hijioka, E. Ashihara, I. Tooyama, S. Shimohama and H. Ariga, Effects of a DJ-1-Binding Compound on Spatial Learning and Memory Impairment in a Mouse Model of Alzheimer's Disease (1) 67–72
- Kiuchi, Y., see Ibrahim, N.F. (2) 597–612
- Kivipelto, M., see Håkansson, K. (2) 645–657
- Kivipelto, M., see Pekkala, T. (3) 1055–1067
- Kiyohara, A.C., see Rueli, R.H.L.H. (2) 749–762
- Kiyohara, Y., see Hamasaki, H. (2) 613–624
- Klockgether, T., see Dronse, J. (2) 465–471
- Klöppel, S., see Araque Caballero, M.Á. (1) 343–358
- Knopman, D.S., see Savica, R. (2) 559–567
- Knopman, D.S., see Vemuri, P. (3) 1069–1082
- Ko, J.W., see Han, J.W. (2) 787–796
- Kobayashi, H., see Moss, D.E. (3) 1285–1294
- Koch, G., see Serra, L. (1) 421–430
- Koh, Y.H., see Shim, S.-M. (1) 293–301
- Kohara, K., see Igase, M. (4) 1481–1487
- Komatsu, J., see Noguchi-Shinohara, M. (3) 905–913
- Koopmans, R., see Mariani, E. (4) 1621–1638
- Kornhuber, J., see Lewczuk, P. (1) 159–170
- Kornhuber, J., see Lewczuk, P. (2) 813–822
- Koscik, R.L., see Darst, B.F. (2) 473–484
- Koudstaal, P.J., see Wolters, F.J. (3) 893–897
- Kourtidou, E., see Paraskevas, G.P. (4) 1453–1461
- Kovac, A., see Banks, W.A. (1) 411–419
- Koyama, S., see Hamasaki, H. (2) 613–624
- Krause, R.A., see Darst, B.F. (2) 473–484
- Krishnan, K., M.M. Machulda, J.L. Whitwell, A.M. Butts, J.R. Duffy, E.A. Strand, M.L. Senjem, A.J. Spychalla, C.R. Jack Jr., V.J. Lowe and K.A. Josephs, Varying Degrees of Temporoparietal Hypometabolism on FDG-PET

- Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity (3) 1019–1029
- Kuceyeski, A., see Pandya, S. (4) 1639–1657
- Kugler, A.R., see Cebers, G. (3) 1039–1053
- Kuhnert, G., see Dronse, J. (2) 465–471
- Kukolja, J., see Dronse, J. (2) 465–471
- Kurumatani, N., see Okamoto, N. (2) 575–583
- Küstners, B., see H. Bea Kuiperij, (2) 585–595
- Kuuluvainen, L., M. Pöyhönen, P. Pasanen, M. Siitonen, J. Rummukainen, P.J. Tienari, A. Paetau and L. Myllykangas, A Novel Loss-of-Function GRN Mutation p.(Tyr229*): Clinical and Neuropathological Features (3) 1167–1174
- Kwak, K.P., see Jacob, L. (1) 259–267
- Laatikainen, T., see Pekkala, T. (3) 1055–1067
- Lacas-Gervais, S., see Prete, D.D. (4) 1549–1570
- Lachmann, I., see Lewczuk, P. (1) 159–170
- Laczó, J., see Pařízková, M. (3) 951–964
- Laffon, B., see Valdiguésias, V. (4) 1509–1517
- Laisney, M., see Duclos, H. (2) 459–463
- Laiterä, T., J. Paananen, S. Helisalimi, T. Sarajärvi, J. Huovinen, M. Laitinen, T. Rauramaa, I. Alafuzoff, A.M. Remes, H. Soininen, A. Haapasalo, J.E. Jääskeläinen, V. Leinonen and M. Hiltunen, Effects of Alzheimer's Disease-Associated Risk Loci on Amyloid- β Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients (3) 995–1003
- Laitinen, M., see Laiterä, T. (3) 995–1003
- Lakshminarayan, K., see Vemuri, P. (3) 1069–1082
- Lanctôt, K.L., see Chau, S.A. (4) 1339–1349
- Langlois, X., see Waldron, A.-M. (4) 1537–1548
- Lapidus, J.A., see Lusardi, T.A. (3) 1223–1233
- Laske, C., see Muller, S. (4) 1463–1469
- Laton, J., see Goossens, J. (1) 53–58
- Lattanzio, F., see Rumeileh, S.A. (4) 1471–1480
- Launay, C.P., see Beauchet, O. (3) 965–971
- Lawrence, C.B., see Martins, I.V.A. (3) 915–932
- Ledreux, A., see Håkansson, K. (2) 645–657
- Lee, C., see Myung, W. (1) 283–292
- Lee, D., see Kim, Y. (2) 485–495
- Lee, D.Y., see Jacob, L. (1) 259–267
- Lee, H., see Han, J.W. (2) 787–796
- Lee, J.-H., see Myung, W. (1) 283–292
- Lee, J.J., see Jacob, L. (1) 259–267
- Lee, J.J., see Kim, Y. (2) 485–495
- Lee, J.-M., see Kim, Y. (2) 485–495
- Lee, M., J.-P. Guo, K. Kennedy, E.G. McGeer and P.L. McGeer, A Method for Diagnosing Alzheimer's Disease Based on Salivary Amyloid- β Protein 42 Levels (3) 1175–1182
- Lee, N.-J., see Han, J.W. (2) 787–796
- Lee, P.H., see Kim, Y. (2) 485–495
- Lee, S., see Huey, E.D. (2) 551–558
- Lee, S.B., see Jacob, L. (1) 259–267
- Lee, S.-K., see Kim, Y. (2) 485–495
- Leentjens, A.F.G., see Jansen, W.J. (2) 679–689
- Legati, A., see Fong, J.C. (1) 249–258
- Leger, D., M. Elbaz, A. Dubois, S. Rio, H. Mezghiche, P. Carita, J. Stemmelin and M. Strauss, Alzheimer's Disease Severity is Not Significantly Associated with Short Sleep: Survey by Actigraphy on 208 Mild and Moderate Alzheimer's Disease Patients (1) 321–331
- Leinonen, V., see Laiterä, T. (3) 995–1003
- Lelental, N., see Lewczuk, P. (1) 159–170
- Lerch, O., see Pařízková, M. (3) 951–964
- Leucht, S., see Fleiner, T. (4) 1583–1594
- Levinoff, E.J., see Beauchet, O. (3) 965–971
- Lewczuk, P., A. Matzen, K. Blennow, L. Parnetti, J.L. Molinuevo, P. Eusebi, J. Kornhuber, J.C. Morris and A.M. Fagan, Cerebrospinal Fluid A β _{42/40} Corresponds Better than A β ₄₂ to Amyloid PET in Alzheimer's Disease (2) 813–822
- Lewczuk, P., N. Lelental, I. Lachmann, M. Holzer, K. Flach, S. Brandner, S. Engelborghs, C.E. Teunissen, H. Zetterberg, J.L. Molinuevo, B. Mroczko, K. Blennow, J. Popp, L. Parnetti, D. Chiasserini, A. Perret-Liaudet, P. Spitzer, J.M. Maler and J. Kornhuber, Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization (1) 159–170
- Li, B., see McClure, R. (2) 797–811
- Li, H., see Tong, Z. (3) 1031–1038
- Li, Q., see Zhang, Y.-P. (2) 497–507
- Li, X., see Chang, P. (1) 77–87
- Li, X., see Sun, L. (2) 777–785
- Li, X.-M., see Wang, Y. (4) 1683–1692
- Lim, N.K.H., see Shen, Y. (2) 835–847
- Lim, S.-W., see Myung, W. (1) 283–292
- Lin, F., P. Ren, R.Y. Lo, B.P. Chapman, A. Jacobs, T.M. Baran, A.P. Porsteinsson and J.J. Foxe for the Alzheimer's Disease Neuroimaging Initiative, Insula and Inferior Frontal Gyrus' Activities Protect Memory Performance Against Alzheimer's Disease Pathology in Old Age (2) 669–678
- Lin, K.A., C. Rundel, P.M. Doraiswamy, for the Alzheimer's Disease Neuroimaging Initiative,

- Serum SHBG Levels are not Associated with Longitudinal Cognitive Decline in Mild Cognitive Impairment (3) 1123–1130
- Lind, B., see Lusardi, T.A. (3) 1223–1233
- Liu, W., see Xie, B. (2) 509–520
- Liu, Z., see Chang, P. (1) 77–87
- Liu, Z., see Xie, B. (2) 509–520
- Lladó, A., see Grau-Rivera, O. (1) 431–443
- Lleo, A., see Carmona-Iragui, M. (4) 1489–1496
- Lleó, A., see Gamir-Morralla, A. (4) 1327–1333
- Lo, R.Y., see Lin, F., (2) 669–678
- Logroscino, G., see Papazacharias, A. (3) 973–979
- Lombino, F., see Sainaghi, P.P. (1) 59–65
- Lomeña, F., see Buongiorno, M. (3) 1261–1272
- Lopera, F., see Abrevaya, S. (4) 1429–1435
- Lopera, F., see Ochoa, J.F. (3) 1195–1205
- López, O.L., see Slachevsky, A. (4) 1595–1603
- Lorenzo-López, L., see Valdiglesias, V. (4) 1509–1517
- Lötjönen, J., see Pekkala, T. (3) 1055–1067
- Lott, I.T., see Coskun, P. (2) 737–748
- Louie, A., see Hilt, S. (4) 1667–1681
- Lowe, V.J., see Krishnan, K. (3) 1019–1029
- Lozupone, M., see Papazacharias, A. (3) 973–979
- Lu, K.P., see Fisher, C.L. (1) 391–410
- Lundt, E.S., see Vemuri, P. (3) 1069–1082
- Luo, H., see Tong, Z. (3) 1031–1038
- Luo, W., see Tong, Z. (3) 1031–1038
- Lusardi, T.A., J.I. Phillips, J.T. Wiedrick, C.A. Harrington, B. Lind, J.A. Lapidus, J.F. Quinn and J.A. Saugstad, MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease (3) 1223–1233
- Luthman, J., see Arnerić, S.P. (1) 19–35
- Lv, J., see Tong, Z. (3) 1031–1038
- Ma, C., see Chang, P. (1) 77–87
- Ma, F., see Zhang, Y.-P. (2) 497–507
- Maccioni, R.B., see Slachevsky, A. (4) 1595–1603
- Machulda, M.M., see Krishnan, K. (3) 1019–1029
- Machulda, M.M., see Savica, R. (2) 559–567
- Macpherson, H., see Kennedy, G. (1) 1–18
- Maezawa, I., see Hilt, S. (4) 1667–1681
- Magnani, G., see Cerami, C. (1) 183–197
- Mahabadi, A.A., see Kara, K. (1) 359–369
- Maikusa, N., see Beheshti, I. (4) 1571–1582
- Majerova, P., see Banks, W.A. (1) 411–419
- Maler, J.M., see Lewczuk, P. (1) 159–170
- Maletta, R.G., see Cupidi, C. (3) 1249–1259
- Maltby, J., see Cebers, G. (3) 1039–1053
- Manabe, T., see Iwahara, N. (3) 1235–1247
- Mañanas, M.A., see Ochoa, J.F. (3) 1195–1205
- Mancini, M., see Serra, L. (1) 421–430
- Marcone, A., see Cerami, C. (1) 183–197
- Mariani, E., R. Chattat, M. Vernooij-Dassen, R. Koopmans and Y. Engels, Care Plan Improvement in Nursing Homes: An Integrative Review (4) 1621–1638
- Marková, H., see Pařízková, M. (3) 951–964
- Marra, C., see Serra, L. (1) 421–430
- Marti, M.J., see Buongiorno, M. (3) 1261–1272
- Martin, J.-J., see Goossens, J. (1) 53–58
- Martins, I.V.A., J. Rivers-Auty, S.M. Allan and C.B. Lawrence, Mitochondrial Abnormalities and Synaptic Loss Underlie Memory Deficits Seen in Mouse Models of Obesity and Alzheimer's Disease (3) 915–932
- Maseda, A., see Valdiglesias, V. (4) 1509–1517
- Maserati, M.S., see Rumeileh, S.A. (4) 1471–1480
- Massion, P., see McClure, R. (2) 797–811
- Matsuda, H., see Beheshti, I. (4) 1571–1582
- Matsumura, A., see Iwahara, N. (3) 1235–1247
- Matsunari, I., see Noguchi-Shinohara, M. (3) 905–913
- Matsushita, T., see Iwahara, N. (3) 1235–1247
- Mattila, J., see Pekkala, T. (3) 1055–1067
- Matzen, A., see Lewczuk, P. (2) 813–822
- Maurice, T., see Rodríguez Cruz, Y. (1) 231–248
- McClure, R., H. Ong, V. Janve, S. Barton, M. Zhu, B. Li, M. Dawes, W.G. Jerome, A. Anderson, P. Massion, J.C. Gore and W. Pham, Aerosol Delivery of Curcumin Reduced Amyloid- β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer's Disease (2) 797–811
- McGeer, E.G., see Lee, M. (3) 1175–1182
- McGeer, P.L., see Lee, M. (3) 1175–1182
- McKeith, I., see Cummings, J. (3) 1131–1139
- Mechanic-Hamilton, D., see Quarmley, M. (4) 1497–1507
- Medina, J.M., see Domínguez-Prieto, M. (1) 171–182
- Meibach, R., see Arnerić, S.P. (1) 19–35
- Mendiola-Precoma, J., K. Padilla, A. Rodríguez-Cruz, L.C. Berumen, R. Miledi and G. García-Alcocer, Theobromine-Induced Changes in A₁ Purinergic Receptor Gene Expression and Distribution in a Rat Brain Alzheimer's Disease Model (3) 1273–1283
- Meng, S., see Shen, Y. (2) 835–847
- Mezghiche, H., see Leger, D. (1) 321–331
- Miao, R., see Zhang, Y.-P. (2) 497–507
- Michalowsky, B., see Wucherer, D. (2) 691–701
- Mielke, M.M., see Savica, R. (2) 559–567

- Miledi, R., see Mendiola-Precoma, J. (3) 1273–1283
- Millán-Calenti, J.C., see Valdiglesias, V. (4) 1509–1517
- Miller, B.L., see Fong, J.C. (1) 249–258
- Miller, Z.A., see Fong, J.C. (1) 249–258
- Mirabelli, M., see Cupidi, C. (3) 1249–1259
- Miranda, L.F.J.R., K.B. Gomes, P.A.L. Tito, J.N. Silveira, G.A. Pianetti, R.M.D. Byrro, P.R.H. Peles, F.H. Pereira, T.R. Santos, A.G. Assini, V.V. Ribeiro, E.N. Moraes and P. Caramelli, Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms (2) 539–549
- Mitra, V., see Russell, C.L. (1) 303–313
- Moberg, P.J., see Quarmley, M. (4) 1497–1507
- Moebus, S., see Kara, K. (1) 359–369
- Mohammed, A.K.H., see Håkansson, K. (2) 645–657
- Molinuevo, J.L., see Grau-Rivera, O. (1) 431–443
- Molinuevo, J.L., see Lewczuk, P. (1) 159–170
- Molinuevo, J.L., see Lewczuk, P. (2) 813–822
- Möller, C., see Hafkemeijer, A. (2) 521–537
- Monacelli, F., M. Cea, R. Borghi, P. Odetti and A. Nencioni, Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease (4) 1295–1306
- Montagnese, S., see Cagnin, A. (4) 1529–1536
- Monté, G.C., see Grau-Rivera, O. (1) 431–443
- Moon, S.W., see Jacob, L. (1) 259–267
- Moon, Y., see Ryu, H.J. (4) 1395–1401
- Moraes, E.N., see Miranda, L.F.J.R. (2) 539–549
- Moreira, P.I., see Ruehli, R.H.L.H. (2) 749–762
- Morikawa, M., see Okamoto, N. (2) 575–583
- Morris, J.C., see Lewczuk, P. (2) 813–822
- Moss, D.E., R.G. Perez and H. Kobayashi, Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates (3) 1285–1294
- Mroczko, B., see Lewczuk, P. (1) 159–170
- Mubeen, A.M., see Ardekani, B.A. (1) 269–281
- Mugantseva, E., see Gureviciene, I. (1) 147–157
- Muller, S., O. Preische, P. Heymann, U. Elbing and C. Laske, Diagnostic Value of a Tablet-Based Drawing Task for Discrimination of Patients in the Early Course of Alzheimer's Disease from Healthy Individuals (4) 1463–1469
- Mummery, C.J., see Golden, H.L. (3) 933–949
- Munoz, D.G., see Kim, J. (1) 381–389
- Munoz, D.G., see Sennik, S. (4) 1519–1528
- Muñoz-Neira, C., see Slachevsky, A. (4) 1595–1603
- Muraca, M.G., see Cupidi, C. (3) 1249–1259
- Murad, H., see Cohen-Manheim, I. (3) 1207–1221
- Murray, A.M., see Vemuri, P. (3) 1069–1082
- Must, A., see Nemeth, V.L. (3) 865–880
- Myllykangas, L., see Kuuluvainen, L. (3) 1167–1174
- Myung, W., C. Lee, J.H. Park, S.-y. Woo, S. Kim, S. Kim, J.W. Chung, H.S. Kang, S.-W. Lim, J. Choi, D.L. Na, S.Y. Kim, J.-H. Lee, S.-H. Han, S.H. Choi, S.Y. Kim, B.J. Carroll and D.K. Kim, Occupational Attainment as Risk Factor for Progression from Mild Cognitive Impairment to Alzheimer's Disease: A CREDOS Study (1) 283–292
- Na, D.L., see Myung, W. (1) 283–292
- Nagels, G., see Goossens, J. (1) 53–58
- Nakamura, H., see Noguchi-Shinohara, M. (3) 905–913
- Nardini, M., see Papazacharias, A. (3) 973–979
- Naudé, P.J.W., see Dekens, D.W. (2) 763–776
- Nemati, Z., see Coskun, P. (2) 737–748
- Nemeth, V.L., A. Must, S. Horvath, A. Király, Z.T. Kincses and L. Vécsei, Gender-Specific Degeneration of Dementia-Related Subcortical Structures Throughout the Lifespan (3) 865–880
- Nencioni, A., see Monacelli, F. (4) 1295–1306
- Neumaier, B., see Dronse, J. (2) 465–471
- Neumann, T., see Kara, K. (1) 359–369
- Newhouse, S., see Voyle, N. (4) 1417–1427
- Ng, L.L., see Peh, C.X. (2) 823–833
- Ngah, W.Z.W. W.Z.W., see Ibrahim, N.F. (2) 597–612
- Ngandu, T., see Pekkala, T. (3) 1055–1067
- Nicholas, J.M., see Golden, H.L. (3) 933–949
- Nicholson, L.K., see Fisher, C.L. (1) 391–410
- Nielson, K.A., see Reiter, K. (4) 1363–1377
- Nilson, A.N., K.C. English, J.E. Gerson, T.B. Whittle, C.N. Crain, J. Xue, U. Sengupta, D.L. Castillo-Carranza, W. Zhang, P. Gupta and R. Kaye, Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases (3) 1083–1099
- Ninomiya, T., see Hamasaki, H. (2) 613–624
- Noguchi-Shinohara, M., J. Komatsu, M. Samuraki, I. Matsunari, T. Ikeda, K. Sakai, T. Hamaguchi, K. Ono, H. Nakamura and M. Yamada, Cerebral Amyloid Angiopathy-Related Microbleeds and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease (3) 905–913
- Nos, C., see Grau-Rivera, O. (1) 431–443
- Nunomura, A., X. Zhu and G. Perry, Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration (1) 73–75

- Ochi, M., see Igase, M. (4) 1481–1487
- Ochoa, J.F., J.F. Alonso, J.E. Duque, C.A. Tobón, M.A. Mañanas, F. Lopera and A.M. Hernández, Successful Object Encoding Induces Increased Directed Connectivity in Presymptomatic Early-Onset Alzheimer's Disease (3) 1195–1205
- Odetti, P., see Monacelli, F. (4) 1295–1306
- Oh, J.M., see Darst, B.F. (2) 473–484
- Ohara, M., see Igase, M. (4) 1481–1487
- Ohara, T., see Hamasaki, H. (2) 613–624
- Ohyagi, Y., see Igase, M. (4) 1481–1487
- Okada, Y., see Igase, M. (4) 1481–1487
- Okamoto, N., M. Morikawa, N. Amano, M. Yanagi, S. Takasawa and N. Kurumatani, Effects of Tooth Loss and the Apolipoprotein E ϵ 4 Allele on Mild Memory Impairment in the Fujiwara-kyo Study of Japan: A Nested Case-Control Study (2) 575–583
- Okamoto, T., see Hamasaki, H. (2) 613–624
- Okonkwo, O.C., see Darst, B.F. (2) 473–484
- Olcese, J., see Beesley, S. (3) 1155–1166
- Oleksik, A.M., see Jansen, W.J. (2) 679–689
- Olsson, T., see Cebers, G. (3) 1039–1053
- Ong, H., see McClure, R. (2) 797–811
- Ono, K., see Ibrahim, N.F. (2) 597–612
- Ono, K., see Noguchi-Shinohara, M. (3) 905–913
- Onur, O.A., see Dronse, J. (2) 465–471
- Ormel, P.R., see Philippens, I.H. (1) 101–113
- Oulès, B., see Prete, D.D. (4) 1549–1570
- Ou-Yang, M.-H., see Anderson, M. (3) 1109–1121
- Paananen, J., see Laiterä, T. (3) 995–1003
- Padilla, K., see Mendiola-Precoma, J. (3) 1273–1283
- Pae, C.-U., see Han, J.W. (2) 787–796
- Paetau, A., see Kuuluvainen, L. (3) 1167–1174
- Pandya, S., A. Kuceyeski and A. Raj for the Alzheimer's Disease Neuroimaging Initiative, The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease (4) 1639–1657
- Panza, F., see Papazacharias, A. (3) 973–979
- Papazacharias, A., M. Lozupone, M.R. Barulli, R. Capozzo, B.P. Imbimbo, F. Veneziani, R. De Blasi, M. Nardini, D. Seripa, F. Panza and G. Logroscino, Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association (3) 973–979
- Pařízková, M., R. Andel, O. Lerch, H. Marková, I. Gažová, M. Vyhnálek, J. Hort and J. Laczó, Homocysteine and Real-Space Navigation Performance among Non-Demented Older Adults (3) 951–964
- Paraskevas, G.P., D. Kasselimis, E. Kourtidou, V. Constantinides, A. Bougea, C. Potagas, I. Evdokimidis and E. Kapaki, Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia (4) 1453–1461
- Parchi, P., see Rumeileh, S.A. (4) 1471–1480
- Park, J.H., see Jacob, L. (1) 259–267
- Park, J.H., see Myung, W. (1) 283–292
- Park, K.-w., see An, H. (2) 727–735
- Park, S.Y., see Kim, H.-R. (1) 137–146
- Park, Y.H., see Kim, H.-R. (1) 137–146
- Parnetti, L., see Lewczuk, P. (1) 159–170
- Parnetti, L., see Lewczuk, P. (2) 813–822
- Pasanen, P., see Kuuluvainen, L. (3) 1167–1174
- Pásaro, E., see Valdiglesias, V. (4) 1509–1517
- Pascual-Leone, A., see Fried, P.J. (1) 89–100
- Pasquier, F., see Wawrziczny, E. (2) 703–716
- Patel, H., see Voyle, N. (4) 1417–1427
- Paterlini, A., see H. Bea Kuiperij, (2) 585–595
- Paterlini-Bréchet, P., see Prete, D.D. (4) 1549–1570
- Paterson, R.W., see Golden, H.L. (3) 933–949
- Pautassi, R., see Abrevaya, S. (4) 1429–1435
- Pavia, J., see Buongiorno, M. (3) 1261–1272
- Peh, C.X., E. Abidin, J.A. Vaingankar, S. Verma, B.Y. Chua, V. Sagayadevan, E. Seow, Y. Zhang, S. Shahwan, L.L. Ng, M. Prince, S.A. Chong and M. Subramaniam, Validation of a Latent Construct for Dementia in a Population-Wide Dataset from Singapore (2) 823–833
- Pekkala, T., A. Hall, J. Lötjönen, J. Mattila, H. Soininen, T. Ngandu, T. Laatikainen, M. Kivipelto and A. Solomon, Development of a Late-Life Dementia Prediction Index with Supervised Machine Learning in the Population-Based CAIDE Study (3) 1055–1067
- Pelagallo, E., see Cerami, C. (1) 183–197
- Peles, P.R.H., see Miranda, L.F.J.R. (2) 539–549
- Perani, D., see Cerami, C. (1) 183–197
- Pereira, F.H., see Miranda, L.F.J.R. (2) 539–549
- Perestelo-Pérez, L., see Rivero-Santana, A. (2) 625–644
- Perez, R.G., see Moss, D.E. (3) 1285–1294
- Perret-Liaudet, A., see Lewczuk, P. (1) 159–170
- Perry, G. see Nunomura, A. (1) 73–75
- Perry, G., see Rueli, R.H.L.H. (2) 749–762
- Petersen, R.C., see Savica, R. (2) 559–567
- Petersen, S., S. Houston, H. Qin, C. Tague and J. Studley, The Utilization of Robotic Pets in Dementia Care (2) 569–574
- Pham, W., see McClure, R. (2) 797–811
- Philippens, I.H., P.R. Ormel, G. Baarends, M. Johansson, E.J. Remarque and M. Doverskog,

- Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer's Disease (1) 101–113
- Phillips, J.I., see Lusardi, T.A. (3) 1223–1233
- Pianetti, G.A., see Miranda, L.F.J.R. (2) 539–549
- Pijnenburg, Y.A.L., see H. Bea Kuiperij, (2) 585–595
- Pijnenburg, Y.A.L., see Hafkemeijer, A. (2) 521–537
- Pike, I., see Russell, C.L. (1) 303–313
- Pinchas-Mizrachi, R., see Cohen-Manheim, I. (3) 1207–1221
- Pineda, D., see Abrevaya, S. (4) 1429–1435
- Pinton, P., see Prete, D.D. (4) 1549–1570
- Pipingas, A., see Kennedy, G. (1) 1–18
- Pirisi, M., see Sainaghi, P.P. (1) 59–65
- Pistilli, A., see Crispoltoni, L. (3) 1005–1017
- Popp, J., see Lewczuk, P. (1) 159–170
- Porsteinsson, A.P., see Lin, F., (2) 669–678
- Potagas, C., see Paraskevas, G.P. (4) 1453–1461
- Pöyhönen, M., see Kuuluvainen, L. (3) 1167–1174
- Preische, O., see Muller, S. (4) 1463–1469
- Prete, D.D., J.M. Suski, B. Oulès, D. Debayle, A.S. Gay, S. Lacas-Gervais, R. Bussiere, C. Bauer, P. Pinton, P. Paterlini-Bréchet, M.R. Wieckowski, F. Checler and M. Chami, Localization and Processing of the Amyloid- Protein Precursor in Mitochondria-Associated Membranes (4) 1549–1570
- Prince, M., see Peh, C.X. (2) 823–833
- Puccio, G., see Cupidi, C. (3) 1249–1259
- Qin, H., see Petersen, S. (2) 569–574
- Quarmley, M., P.J. Moberg, D. Mechanic-Hamilton, S. Kabadi, S.E. Arnold, D.A. Wolk and D.R. Roalf, Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer's Disease (4) 1497–1507
- Quinn, J.F., see Lusardi, T.A. (3) 1223–1233
- Raaphorst, J., see H. Bea Kuiperij, (2) 585–595
- Racine, A.M., see Darst, B.F. (2) 473–484
- Ræder, J., see Idland, A.-V. (1) 371–379
- Raha, A.A., J.W. Henderson, S.R.W. Stott, R. Vuono, S. Foscarin, R.P. Friedland, S.H. Zaman and R. Raha-Chowdhury, Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model (1) 199–217
- Raha-Chowdhury, R., see Raha, A.A. (1) 199–217
- Raj, A., see Pandya, S. (4) 1639–1657
- Ralph, J., see Fong, J.C. (1) 249–258
- Ramakers, I.H.G.B., see Jansen, W.J. (2) 679–689
- Ramirez, I., see Buongiorno, M. (3) 1261–1272
- Rankin, K.P., see Fong, J.C. (1) 249–258
- Rao, S.M., see Reiter, K. (4) 1363–1377
- Raunig, D., see Arnerić, S.P. (1) 19–35
- Rauramaa, T., see Laiterä, T. (3) 995–1003
- Reid, R.I., see Vemuri, P. (3) 1069–1082
- Reiter, K., K.A. Nielson, S. Durgerian, J.L. Woodard, J.C. Smith, M. Seidenberg, D.A. Kelly and S.M. Rao, Five-Year Longitudinal Brain Volume Change in Healthy Elders at Genetic Risk for Alzheimer's Disease (4) 1363–1377
- Remarque, E.J., see Philippens, I.H. (1) 101–113
- Remes, A.M., see Laiterä, T. (3) 995–1003
- Ren, P., see Lin, F., (2) 669–678
- Rende, M., see Crispoltoni, L. (3) 1005–1017
- Resnick, R.J., see Fisher, C.L. (1) 391–410
- Reyes, P., see Slachevsky, A. (4) 1595–1603
- Ribeiro, V.V., see Miranda, L.F.J.R. (2) 539–549
- Ricci, C., see Zimetti, F., (1) 315–320
- Richardson, J.C., see Waldron, A.-M. (4) 1537–1548
- Richter, S., see Wucherer, D. (2) 691–701
- Rikkert, M.O., see Freeze, W.M. (1) 333–342
- Rikkert, M.O., see Jansen, W.J. (2) 679–689
- Rio, S., see Leger, D. (1) 321–331
- Ríos, J., see Buongiorno, M. (3) 1261–1272
- Riva, G., see Serino, S. (3) 881–892
- Rivero-Santana, A., D. Ferreira, L. Perestelo-Pérez, E. Westman, L.-O. Wahlund, A. Sarría and P. Serrano-Aguilar, Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors (2) 625–644
- Rivers-Auty, J., see Martins, I.V.A. (3) 915–932
- Rizzi, R., see Rumeileh, S.A. (4) 1471–1480
- Roalf, D.R., see Quarmley, M. (4) 1497–1507
- Roberts, R.O., see Savica, R. (2) 559–567
- Robillard, J.M. and T.L. Feng, Health Advice in a Digital World: Quality and Content of Online Information about the Prevention of Alzheimer's Disease (1) 219–229
- Robinson, J.K., see Anderson, M. (3) 1109–1121
- Rochina, M.J., see de la Rubia Ortí, J.E. (3) 899–903
- Rockwood, K., see Cummings, J. (3) 1131–1139
- Rodríguez Cruz, Y., M. Strehaiano, T. Rodríguez Obaya, J.C.G. Rodríguez and T. Maurice, An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APP^{Swe} Transgenic Mouse Model of Alzheimer's Disease (1) 231–248

- Rodríguez Obaya, T., see Rodríguez Cruz, Y. (1) 231–248
- Rodríguez, J.C.G., see Rodríguez Cruz, Y. (1) 231–248
- Rodríguez-Cruz, A., see Mendiola-Precoma, J. (3) 1273–1283
- Rojas, J.C., see Fong, J.C. (1) 249–258
- Romanello, M., see Cupidi, C. (3) 1249–1259
- Rombouts, S.A.R.B., see Hafkemeijer, A. (2) 521–537
- Romero, K., see Arnerić, S.P. (1) 19–35
- Ronda, N., see Zimetti, F., (1) 315–320
- Rosen, L., see Cebers, G. (3) 1039–1053
- Rueli, R.H.L.H., D.J. Torres, A.S.T. Dewing, A.C. Kiyohara, S.M. Barayuga, M.T. Bellinger, J.H. Uyehara-Lock, L.R. White, P.I. Moreira, M.J. Berry, G. Perry and F.P. Bellinger, Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology (2) 749–762
- Rumeileh, S.A., F. Lattanzio, M.S. Maserati, R. Rizzi, S. Capellari and P. Parchi, Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and A β ₄₂ in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants (4) 1471–1480
- Rummukainen, J., see Kuuluvainen, L. (3) 1167–1174
- Rundel, C., see Lin, K.A. (3) 1123–1130
- Ruscica, M., see Zimetti, F., (1) 315–320
- Russell, C.L., V. Mitra, K. Hansson, K. Blennow, J. Gobom, H. Zetterberg, M. Hiltunen, M. Ward and I. Pike, Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates (1) 303–313
- Russell, M., see Cebers, G. (3) 1039–1053
- Ryu, H.J., M. Kim, Y. Moon, Y. Choi, J.-Y. Han, J.E. Galvin and S.-H. Han, Validation of the Korean Version of the Lewy Body Composite Risk Score (K-LBCRS) (4) 1395–1401
- Ryu, S.-H., see Han, J.W. (2) 787–796
- Ryu, S.-H., see Jacob, L. (1) 259–267
- Sagayadevan, V., see Peh, C.X. (2) 823–833
- Sager, M.A., see Darst, B.F. (2) 473–484
- Sainaghi, P.P., M. Bellan, F. Lombino, F. Alciato, M. Carecchio, D. Galimberti, C. Fenoglio, E. Scarpini, R. Cantello, M. Pirisi and C. Comi, Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease (1) 59–65
- Saito, T., see Iwahara, N. (3) 1235–1247
- Sakai, K., see Noguchi-Shinohara, M. (3) 905–913
- Salazar, F., see Buongiorno, M. (3) 1261–1272
- Samtani, M.N., see Arnerić, S.P. (1) 19–35
- Samuraki, M., see Noguchi-Shinohara, M. (3) 905–913
- Sancesario, G.M., S. Toniolo, D. Chiasserini, S.G. Di Santo, J. Zegeer, G. Bernardi for SIBioC-Study Group of Clinical Biochemistry of Biological Fluids other than Blood, Massimo Musicco for SINDem-ITALPLANED, Carlo Caltagirone, Lucilla Parnetti and Sergio Bernardini, The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie (4) 1659–1666
- Sanchez-Etayo, G., see Buongiorno, M. (3) 1261–1272
- Sánchez-Valle, R., see Grau-Rivera, O. (1) 431–443
- Santangelo, R., see Cerami, C. (1) 183–197
- Santos, T., see Carmona-Iragui, M. (4) 1489–1496
- Santos, T.R., see Miranda, L.F.J.R. (2) 539–549
- Sarajärvi, T., see Laiterä, T. (3) 995–1003
- Sarno, T.A., L.L. Talib, H.P.G. Joaquim, J.M. de França Bram, W.F. Gattaz and O.V. Forlenza, Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets (4) 1445–1451
- Sarria, A., see Rivero-Santana, A. (2) 625–644
- Sato, S., see Kazui, H. (4) 1403–1416
- Saugstad, J.A., see Lusardi, T.A. (3) 1223–1233
- Saunders, C., see Beesley, S. (3) 1155–1166
- Savage, M., see Arnerić, S.P. (1) 19–35
- Savica, R., A.M.V. Wennberg, C. Hagen, K. Edwards, R.O. Roberts, J.H. Hollman, D.S. Knopman, B.F. Boeve, M.M. Machulda, R.C. Petersen and M.M. Mielke, Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging (2) 559–567
- Saxena, S., see Fried, P.J. (1) 89–100
- Scarpini, E., see Sainaghi, P.P. (1) 59–65
- Schelhaas, H.J., see H. Bea Kuiperij, (2) 585–595
- Scheltens, P., see Cummings, J. (3) 1131–1139
- Scheltens, P., see Hafkemeijer, A. (2) 521–537
- Scheltens, P., see Jansen, W.J. (2) 679–689
- Schena, F., see Crispoltoni, L. (3) 1005–1017
- Schependom, J.V., see Goossens, J. (1) 53–58
- Schiano, I., see de la Monte, S.M. (2) 849–864

- Schilberg, L., see Fried, P.J. (1) 89–100
- Schmidt, M., see Waldron, A.-M. (4) 1537–1548
- Scholey, A.B., see Kennedy, G. (1) 1–18
- Schott, J.M., see Golden, H.L. (3) 933–949
- Schriner, S.E., see Coskun, P. (2) 737–748
- Schroeder, F.C., see Fisher, C.L. (1) 391–410
- Schweizer, T.A., see Kim, J. (1) 381–389
- Schweizer, T.A., see Sennik, S. (4) 1519–1528
- Sedeño, L., see Abrevaya, S. (4) 1429–1435
- Seidenberg, M., see Reiter, K. (4) 1363–1377
- Sengupta, U., see Nilson, A.N. (3) 1083–1099
- Senjem, M.L., see Krishnan, K. (3) 1019–1029
- Sennik, S., T.A. Schweizer, C.E. Fischer and D.G. Munoz, Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data (4) 1519–1528
- Seow, E., see Peh, C.X. (2) 823–833
- Serino, S. and G. Riva, The Proactive Self in Space: How Egocentric and Allocentric Spatial Impairments Contribute to Anosognosia in Alzheimer's Disease (3) 881–892
- Seripa, D., see Papazacharias, A. (3) 973–979
- Serra, L., M. Mancini, M. Cercignani, C. Di Domenico, B. Spanò, G. Giulietti, G. Koch, C. Marra and M. Bozzali, Network-Based Substrate of Cognitive Reserve in Alzheimer's Disease (1) 421–430
- Serrano-Aguilar, P., see Rivero-Santana, A. (2) 625–644
- Shah, R.C., see Cummings, J. (3) 1131–1139
- Shahwan, S., see Peh, C.X. (2) 823–833
- Shaw, L., see Arnerić, S.P. (1) 19–35
- Shen, Y., Y. Xia, S. Meng, N.K.H. Lim, W. Wang and F. Huang, SH2B1 is Involved in the Accumulation of Amyloid- β_{42} in Alzheimer's Disease (2) 835–847
- Sherman, C., see Chau, S.A. (4) 1339–1349
- Shi, M., see Banks, W.A. (1) 411–419
- Shim, S.-M., H.-S. Cheon, C. Jo, Y.H. Koh, J. Song and J.-P. Jeon, Elevated Epstein-Barr Virus Antibody Level is Associated with Cognitive Decline in the Korean Elderly (1) 293–301
- Shimohama, S., see Iwahara, N. (3) 1235–1247
- Shimohama, S., see Kitamura, Y. (1) 67–72
- Shimosegawa, E., see Kazui, H. (4) 1403–1416
- Sieben, A., see Goossens, J. (1) 53–58
- Siitonen, M., see Kuuluvainen, L. (3) 1167–1174
- Silveira, J.N., see Miranda, L.F.J.R. (2) 539–549
- Simon, E.S., see Cohen-Manheim, I. (3) 1207–1221
- Singh, V., see Hilt, S. (4) 1667–1681
- Sinnreich, R., see Cohen-Manheim, I. (3) 1207–1221
- Slachevsky, A., L. Guzmán-Martínez, C. Delgado, P. Reyes, G.A. Fariás, C. Muñoz-Neira, E. Bravo, M. Fariás, P. Flores, C. Garrido, J.T. Becker, O.L. López and R.B. Maccioni, Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease (4) 1595–1603
- Slattery, C.F., see Golden, H.L. (3) 933–949
- Slinin, Y., see Vemuri, P. (3) 1069–1082
- Smania, N., see Crispoltoni, L. (3) 1005–1017
- Smid, M., see Jansen, W.J. (2) 679–689
- Smirne, N., see Cupidi, C. (3) 1249–1259
- Smith, J.C., see Reiter, K. (4) 1363–1377
- Smith, M.A., see Dengler-Crish, C.M. (4) 1605–1619
- Sohn, Y.H., see Kim, Y. (2) 485–495
- Soininen, H., see Laiterä, T. (3) 995–1003
- Soininen, H., see Pekkala, T. (3) 1055–1067
- Soler, M., see Buongiorno, M. (3) 1261–1272
- Solomon, A., see Pekkala, T. (3) 1055–1067
- Song, J., see Shim, S.-M. (1) 293–301
- Song, M., see Xie, B. (2) 509–520
- Spallazzi, M., see Zimetti, F. (1) 315–320
- Spanò, B., see Serra, L. (1) 421–430
- Spitzer, P., see Lewczuk, P. (1) 159–170
- Spychalla, A.J., see Krishnan, K. (3) 1019–1029
- Stabile, A.M., see Crispoltoni, L. (3) 1005–1017
- Staelens, S., see Waldron, A.-M. (4) 1537–1548
- Stemmelin, J., see Leger, D. (1) 321–331
- Stephenson, D., see Arnerić, S.P. (1) 19–35
- Støen, R., see Idland, A.-V. (1) 371–379
- Stott, S.R.W., see Raha, A.A. (1) 199–217
- Strand, E.A., see Krishnan, K. (3) 1019–1029
- Strauss, M., see Leger, D. (1) 321–331
- Strehaiano, M., see Rodríguez Cruz, Y. (1) 231–248
- Strohmaier, U., see Teipel, S.J. (4) 1379–1394
- Stroobants, S., see Waldron, A.-M. (4) 1537–1548
- Struyfs, H., see Goossens, J. (1) 53–58
- Studley J., see Petersen, S. (2) 569–574
- Subramaniam, M., see Peh, C.X. (2) 823–833
- Suehiro, T., see Kazui, H. (4) 1403–1416
- Sun, L., K. Chen, X. Li and S. Xiao, Rapidly Progressive Frontotemporal Dementia Associated with MAPT Mutation G389R (2) 777–785
- Sun, Y., see Wang, Y. (4) 1683–1692
- Suski, J.M., see Prete, D.D. (4) 1549–1570
- Suzuki, H., see Iwahara, N. (3) 1235–1247
- Suzuki, S., see Iwahara, N. (3) 1235–1247
- Suzuki, S.O., see Hamasaki, H. (2) 613–624
- Suzuki, Y., see Kazui, H. (4) 1403–1416

- Szablewski, L., Glucose Transporters in Brain: In Health and in Alzheimer's Disease (4) 1307–1320
- Tabara, Y., see Igase, M. (4) 1481–1487
- Tabernero, A., see Domínguez-Prieto, M. (1) 171–182
- Tague, C., see Petersen, S. (2) 569–574
- Takahashi, R., see Kazui, H. (4) 1403–1416
- Takasawa, S., see Okamoto, N. (2) 575–583
- Takata, K., see Kitamura, Y. (1) 67–72
- Talib, L.L., see Sarno, T.A. (4) 1445–1451
- Tan, H., see Wang, Y. (4) 1683–1692
- Tanaka, T., see Kazui, H. (4) 1403–1416
- Tang, T., see Hilt, S. (4) 1667–1681
- Tanila, H., see Gureviciene, I. (1) 147–157
- Teipel, S., see Wucherer, D. (2) 691–701
- Teipel, S.J., F. Keller, J.R. Thyrian, U. Strohmaier, A. Altiner, W. Hoffmann and I. Kilimann, Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care? (4) 1379–1394
- Terjestam, Y., see Håkansson, K. (2) 645–657
- Teunissen, C.E., see H. Bea Kuiperij, (2) 585–595
- Teunissen, C.E., see Lewczuk, P. (1) 159–170
- Thomas, J., see Coskun, P. (2) 737–748
- Thostenson, K.B., see Vemuri, P. (3) 1069–1082
- Thyrian, J.R., see Teipel, S.J. (4) 1379–1394
- Thyrian, J.R., see Wucherer, D. (2) 691–701
- Tienari, P.J., see Kuuluvainen, L. (3) 1167–1174
- Tito, P.A.L., see Miranda, L.F.J.R. (2) 539–549
- Tobón, C.A., see Ochoa, J.F. (3) 1195–1205
- Tong, M., see de la Monte, S.M. (2) 849–864
- Tong, Z., W. Wang, W. Luo, J. Lv, H. Li, H. Luo, J. Jia and R. He, Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer's Disease (3) 1031–1038
- Toniolo, S., see Sancesario, G.M. (4) 1659–1666
- Tooyama, I., see Ibrahim, N.F. (2) 597–612
- Tooyama, I., see Kitamura, Y. (1) 67–72
- Torchia, G., see Cupidi, C. (3) 1249–1259
- Torres, D.J., see Rueli, R.H.L.H. (2) 749–762
- Tremblay, C., see Dal-Pan, A. (1) 115–135
- Trujillo, N., see Abrevaya, S. (4) 1429–1435
- Tsuji, M., see Ibrahim, N.F. (2) 597–612
- Turco, M., see Cagnin, A. (4) 1529–1536
- Turnbull, M.T. and E.J. Coulson, Cholinergic Basal Forebrain Lesion Decreases Neurotrophin Signaling without Affecting Tau Hyperphosphorylation in Genetically Susceptible Mice (3) 1141–1154
- Ulstein, I. and T. Böhmer, Normal Vitamin Levels and Nutritional Indices in Alzheimer's Disease Patients with Mild Cognitive Impairment or Dementia with Normal Body Mass Indexes (2) 717–725
- Umek, R.M., see Arnerić, S.P. (1) 19–35
- Uyehara-Lock, J.H., see Rueli, R.H.L.H. (2) 749–762
- Vaingankar, J.A., see Peh, C.X. (2) 823–833
- Valdiglesias, V., A. Maseda, L. Lorenzo-López, E. Pásaro, J.C. Millán-Calenti and B. Laffon, Is Salivary Chromogranin A a Valid Psychological Stress Biomarker During Sensory Stimulation in People with Advanced Dementia? (4) 1509–1517
- Valeria De Marco, E., see Cuccaro, D. (1) 37–52
- Valldeoriola, F., see Buongiorno, M. (3) 1261–1272
- Van Broeckhoven, C., see Goossens, J. (1) 53–58
- van Buchem, M.A., see Freeze, W.M. (1) 333–342
- Van Dam, D., see Dekens, D.W. (2) 763–776
- van den Berg-Huysmans, A.A., see Hafkemeijer, A. (2) 521–537
- Van den Bossche, T., see Goossens, J. (1) 53–58
- van der Flier, W.M., see Freeze, W.M. (1) 333–342
- van der Flier, W.M., see Hafkemeijer, A. (2) 521–537
- van der Grond, J., see Hafkemeijer, A. (2) 521–537
- van der Lugt, A., see Wolters, F.J. (3) 893–897
- van der Zee, J., see Goossens, J. (1) 53–58
- van Domburg, P., see Jansen, W.J. (2) 679–689
- van Eimeren, T., see Dronse, J. (2) 465–471
- Van Mossevelde, S., see Goossens, J. (1) 53–58
- Van Nostrand, W.E., see Anderson, M. (3) 1109–1121
- van Swieten, J.C., see Hafkemeijer, A. (2) 521–537
- Vanderstichele, H., see Arnerić, S.P. (1) 19–35
- Varma, V.R. and A. Watts, Daily Physical Activity Patterns During the Early Stage of Alzheimer's Disease (2) 659–667
- Vasso, F., see Cupidi, C. (3) 1249–1259
- Vécsei, L., see Nemeth, V.L. (3) 865–880
- Vega, L., see Domínguez-Prieto, M. (1) 171–182
- Velasco, A., see Domínguez-Prieto, M. (1) 171–182
- Vemuri, P., D.S. Knopman, C.R. Jack Jr, E.S. Lundt, S.D. Weigand, S.M. Zuk, K.B. Thostenson, R.I. Reid, K. Kantarci, Y. Slinin, K. Lakshminarayan, C.S. Davey and A.M. Murray, Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study (3) 1069–1082
- Veneziani, F., see Papazacharias, A. (3) 973–979
- Venturelli, M., see Crispoltoni, L. (3) 1005–1017
- Verbeek, M.M., see Freeze, W.M. (1) 333–342
- Verbeek, M.M., see H. Bea Kuiperij, (2) 585–595
- Verhaeghe, J., see Waldron, A.-M. (4) 1537–1548

- Verhey, F., see Jansen, W.J. (2) 679–689
 Verhey, F.R., see Freeze, W.M. (1) 333–342
 Verma, S., see Peh, C.X. (2) 823–833
 Vermeiren, Y., see Dekens, D.W. (2) 763–776
 Vermette, A., see Bergeron, D. (4) 1335–1337
 Vernooij, M.W., see Wolters, F.J. (3) 893–897
 Vernooij-Dassen, M., see Mariani, E. (4) 1621–1638
 Versleijen, A.A.M., see H. Bea Kuiperij, (2) 585–595
 Verwey, N.A., see H. Bea Kuiperij, (2) 585–595
 Viard, A., see Duclos, H. (2) 459–463
 Videla, L., see Carmona-Iragui, M. (4) 1489–1496
 Videla, S., see Carmona-Iragui, M. (4) 1489–1496
 Villegas, A., see Abrevaya, S. (4) 1429–1435
 Visser, P.J., see Jansen, W.J. (2) 679–689
 Visser, P.J., see Voyle, N. (4) 1417–1427
 von Reutern, B., see Dronse, J. (2) 465–471
 Vos, S.J., see Freeze, W.M. (1) 333–342
 Voshaar, R.C.O., see Dekens, D.W. (2) 763–776
 Voss, J.C., see Hilt, S. (4) 1667–1681
 Voyle, N., H. Patel, A. Folarin, S. Newhouse, C. Johnston, P.J. Visser, R.J.B. Dobson and S.J. Kiddle the EDAR and DESCRIPA study groups and the Alzheimer's Disease Neuroimaging Initiative, Genetic Risk as a Marker of Amyloid- β and Tau Burden in Cerebrospinal Fluid (4) 1417–1427
 Vrenken, H., see Hafkemeijer, A. (2) 521–537
 Vuono, R., see Raha, A.A. (1) 199–217
 Vyhánek, M., see Pařízková, M. (3) 951–964
- Wahlund, L.-O., see Andreotti, J. (3) 981–993
 Wahlund, L.-O., see Rivero-Santana, A. (2) 625–644
 Waldron, A.-M., L. wyffels, J. Verhaeghe, J.C. Richardson, M. Schmidt, S. Stroobants, X. Langlois and S. Staelens, Longitudinal Characterization of [^{18}F]-FDG and [^{18}F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model (4) 1537–1548
 Wallace, D.C., see Coskun, P. (2) 737–748
 Walton, J.H., see Hilt, S. (4) 1667–1681
 Wang, J.-F., see Wang, Y. (4) 1683–1692
 Wang, M.J., see Kim, H.-R. (1) 137–146
 Wang, W., see Shen, Y. (2) 835–847
 Wang, W., see Tong, Z. (3) 1031–1038
 Wang, X., see Xie, B. (2) 509–520
 Wang, Y., see Wang, Y. (4) 1683–1692
 Wang, Y., Z. Zhou, H. Tan, S. Zhu, Y. Wang, Y. Sun, X.-M. Li and J.-F. Wang, Nitrosylation of Vesicular Transporters in Brain of Amyloid Precursor Protein/ Presenilin 1 Double Transgenic Mice (4) 1683–1692
- Ward, M., see Russell, C.L. (1) 303–313
 Warren, J.D., see Golden, H.L. (3) 933–949
 Watne, L.O., see Idland, A.-V. (1) 371–379
 Watts, A., see Varma, V.R. (2) 659–667
 Wawrziczny, E., G. Berna, F. Ducharme, M.-J. Kergoat, F. Pasquier and P. Antoine, Modeling the Distress of Spousal Caregivers of People with Dementia (2) 703–716
 Weigand, S.D., see Vemuri, P. (3) 1069–1082
 Weimar, C., see Kara, K. (1) 359–369
 Wennberg, A.M.V., see Savica, R. (2) 559–567
 Westman, E., see Rivero-Santana, A. (2) 625–644
 White, L.R., see Rueli, R.H.L.H. (2) 749–762
 Whittle, T.B., see Nilson, A.N. (3) 1083–1099
 Whitwell, J.L., see Krishnan, K. (3) 1019–1029
 Wieckowski, M.R., see Prete, D.D. (4) 1549–1570
 Wiedrick, J.T., see Lusardi, T.A. (3) 1223–1233
 Wijker, W., see Cummings, J. (3) 1131–1139
 Wilkinson, D., see Cummings, J. (3) 1131–1139
 Willis, B., see Arnerić, S.P. (1) 19–35
 Wilson, G.N., see Dengler-Criss, C.M. (4) 1605–1619
 Winblad, B., see Håkansson, K. (2) 645–657
 Winkler, A., see Kara, K. (1) 359–369
 Wolfs, C., see Jansen, W.J. (2) 679–689
 Wolk, D.A., see Quarmley, M. (4) 1497–1507
 Wolters, F.J., D. Bos, M.W. Vernooij, O.H. Franco, The Heart-Brain Connection collaborative research group, A. Hofman, P.J. Koudstaal, A. van der Lugt and M.A. Ikram, Aortic Valve Calcification and the Risk of dementia: A Population-Based Study (3) 893–897
 Wong, B., see Fried, P.J. (1) 89–100
 Woo, S.-y., see Myung, W. (1) 283–292
 Woodard, J.L., see Reiter, K. (4) 1363–1377
 Woods, R.T., see Yates, J.A., (3) 1183–1193
 Wu, T., see Zhang, Y.-P. (2) 497–507
 Wucherer, D., T. Eichler, J. Hertel, I. Kilimann, S. Richter, B. Michalowsky, J.R. Thyrian, S. Teipel and W. Hoffmann, Potentially Inappropriate Medication in Community-Dwelling Primary Care Patients who were Screened Positive for Dementia (2) 691–701
 Wulff, H., see Hilt, S. (4) 1667–1681
 wyffels, L., see Waldron, A.-M. (4) 1537–1548
 Wyller, T.B., see Idland, A.-V. (1) 371–379
- Xia, Y., see Shen, Y. (2) 835–847
 Xiao, S., see Sun, L. (2) 777–785
 Xie, B., Z. Liu, L. Jiang, W. Liu, M. Song, Q. Zhang, R. Zhang, D. Cui, X. Wang and S. Xu, Increased

- Serum miR-206 Level Predicts Conversion from Amnesic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study (2) 509–520
- Xing, T., see Zhuang, X. (3) 1101–1108
- Xu, F., see Anderson, M. (3) 1109–1121
- Xu, S., see Xie, B. (2) 509–520
- Xue, J., see Nilson, A.N. (3) 1083–1099
- Yamada, M., see Noguchi-Shinohara, M. (3) 905–913
- Yamamoto, Y., see Kazui, H. (4) 1403–1416
- Yanagi, M., see Okamoto, N. (2) 575–583
- Yanagisawa, D., see Ibrahim, N.F. (2) 597–612
- Yanagisawa, D., see Kitamura, Y. (1) 67–72
- Yang, D.-W., see An, H. (2) 727–735
- Yang, X., see Zhuang, X. (3) 1101–1108
- Yates, J.A., L. Clare and R.T. Woods in collaboration with The Cognitive Function and Ageing Study: Wales, What is the Relationship between Health, Mood, and Mild Cognitive Impairment? (3) 1183–1193
- Ye, B.S., see Kim, Y. (2) 485–495
- Ye, N., see Cebers, G. (3) 1039–1053
- Yokokawa, K., see Iwahara, N. (3) 1235–1247
- Yoon, J.C., see Jacob, L. (1) 259–267
- Yoshiyama, K., see Kazui, H. (4) 1403–1416
- Youn, J.C., see Han, J.W. (2) 787–796
- Yule, S., see Amerić, S.P. (1) 19–35
- Zaman, S.H., see Raha, A.A. (1) 199–217
- Zampieri, S., see Cupidi, C. (3) 1249–1259
- Zanotti, I., see Zimetti, F. (1) 315–320
- Zegeer, J., see Sancesario, G.M. (4) 1659–1666
- Zetterberg, H., see Darst, B.F. (2) 473–484
- Zetterberg, H., see Idland, A.-V. (1) 371–379
- Zetterberg, H., see Lewczuk, P. (1) 159–170
- Zetterberg, H., see Russell, C.L. (1) 303–313
- Zhang, J., see Banks, W.A. (1) 411–419
- Zhang, Q., see Xie, B. (2) 509–520
- Zhang, R., see Xie, B. (2) 509–520
- Zhang, S., see Chang, P. (1) 77–87
- Zhang, W., see Nilson, A.N. (3) 1083–1099
- Zhang, Y., see Peh, C.X. (2) 823–833
- Zhang, Y.-P., R. Miao, Q. Li, T. Wu and F. Ma, Effects of DHA Supplementation on Hippocampal Volume and Cognitive Function in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial (2) 497–507
- Zhang, Z., see Chang, P. (1) 77–87
- Zhou, Z., see Wang, Y. (4) 1683–1692
- Zhu, M., see McClure, R. (2) 797–811
- Zhu, S., see Wang, Y. (4) 1683–1692
- Zhu, X., see Nunomura, A. (1) 73–75
- Zhuang, X., see Zhuang, X. (3) 1101–1108
- Zhuang, X., Y. Chen, X. Zhuang, T. Xing, T. Chen, G. Jiang and X. Yang, Impaired Center-Surround Suppression in Patients with Alzheimer's Disease (3) 1101–1108
- Zijlstra, W., see Fleiner, T. (4) 1583–1594
- Zimetti, F., P. Caffarra, N. Ronda, E. Favari, M.P. Adorni, I. Zanotti, F. Bernini, F. Barocco, M. Spallazzi, D. Galimberti, C. Ricci, M. Ruscica, A. Corsini and N. Ferri, Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease (1) 315–320
- Zuk, S.M., see Vemuri, P. (3) 1069–1082